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ABSTRACT 
Linear bone growth occurs at the growth plate, a thin layer of cartilage between the 
epiphysis and metaphysis of long bones. In the growth plate, resting/stem-like 
chondrocytes divide and generate the highly proliferative chondrocytes, which further 
differentiate into the enlarged hypertrophic form before being substituted by bone, a 
process called endochondral ossification. A precise balance between different factors 
affecting chondrocyte proliferation, differentiation/hypertrophy, matrix synthesis, and cell 
death within the growth plate must exist to ensure normal bone growth. Anti-cancer 
therapy can interfere with any of these processes, thereby affecting chondrogenesis and 
bone growth negatively. Proteasome inhibitors (PIs, e.g., MG262 and bortezomib) are a 
new, novel class of anti-cancer drugs. Bortezomib is approved for the treatment of adult 
hematologic malignancies, and is currently under clinical trials with pediatric cancers. So 
far, any undesired secondary side effects are yet unknown in treated children.  
The aim of this thesis was to address whether PIs affect linear bone growth and 
bone homeostasis, and if so, what the underlying cellular mechanisms are, and to find 
potential ways to protect bone growth during anti-cancer treatment. 
In the first study (Paper I), the effect of the non-clinically used PIs, MG262 and 
lactacystin, were investigated both in vitro and in vivo. Here we report for the first time 
that systemic administration of MG262 specifically targets the growth plate, and impairs 
linear bone growth in treated mice. The effect is linked to increased apoptosis of 
resting/stem-like chondrocytes in a caspase-dependent and independent manner. 
Inhibition of p53 and apoptosis-inducing-factor (AIF) were able to partly rescue from 
MG262-induced chondrocyte apoptosis. 
Since bortezomib is in pediatric clinical trials, it is even more important to delineate 
any possible secondary side effects on linear bone growth and bone homeostasis (Paper 
II). Our results demonstrate that a clinically relevant dose of bortezomib specifically and 
efficiently impairs the ubiquitin/proteasome system (UPS). Consequently, young mice 
display severe growth failure during treatment, as well as after a follow-up period of 6 
months post-treatment. This effect was mediated through a local action of bortezomib in 
the growth plate, causing increased resting/stem-like chondrocyte apoptosis and 
decreased differentiation. We also show that bortezomib mainly acts via the intrinsic 
apoptotic pathway, in which p53 and Bax appear to be the key regulators triggering 
apoptosis. In addition, cultured human growth plate cartilage was confirmed to be 
highly sensitive to bortezomib. 
In an attempt to rescue bone growth during bortezomib treatment, we utilized 
pharmacological inhibition of Bax by the synthetic peptide analog to endogenous 
humanin, [Gly
14
]-Humanin (HNG) (Paper III). We made the novel finding that HNG can 
rescue bone growth during bortezomib treatment by protecting resting/stem-like growth 
plate chondrocytes. Importantly, HNG did not interfere with the desired anti-cancer effect 
of bortezomib as tested and verified in tumor xenograft models as well as several human 
tumor cell lines. HNG also protected cultured human growth plate cartilage from the 
cytotoxic effects of bortezomib. 
In conclusion, our observations confirmed in vivo and in vitro, including human 
growth plate cartilage, suggest that bone growth could potentially be suppressed in 
children treated with PIs. We hereby propose that bone growth and bone mineralization 
should be closely monitored in ongoing pediatric clinical trials. In addition, HNG may 
have the capacity to prevent PI-induced bone growth impairment without interfering with 
the desired anti-cancer effect. 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund: Benets längdtillväxt sker i tillväxtplattan, ett tunt skikt av brosk som 
återfinns i ändarna av de långa rörbenen. Tillväxtplattan består av 3 unika zoner, “den 
vilande” innehållande stamcellslika broskceller (kondrocyter) som övergår till den 
“proliferativa” där cellerna delar sig snabbt för att sedan öka i storlek och ge upphov till 
”hypertrofa” kondrocyter som slutligen dör och ben bildas. Så länge man växer på 
längden finns alltså tillväxtplattan kvar, men under den senare delen av puberteten har den 
helt omvandlats till ben och därmed slutar vi även växa. Cancerbehandling hos unga 
individer kan störa kondrocyternas utveckling, vilket resulterar i tillväxthämning. 
Proteasomhämmare (ex. bortezomib) är en ny, lovande klass av cancermediciner som är i 
kliniska försök på barn, men man vet ännu inte om den har några skadliga effekter på 
normala vävnader och tillväxtplattans kondrocyter och/eller längdtillväxt.  
Frågeställning: Syftet med denna avhandling var att undersöka om/hur 
proteasomhämmare påverkar benens tillväxt och förbening, utreda de bakomliggande 
cellulära mekanismerna och att finna möjliga sätt att skydda tillväxten under pågående 
cancer behandling. 
Experimentella modeller: Olika musmodeller, tillväxtbrosk tillvarataget i 
samband med operation från unga patienter, mellanfotsben från råtta samt odlade 
broskceller från både människa och råtta och även humana cancerceller. 
Resultat: I den första studien (artikel I) har vi studerat effekten av de icke-kliniskt 
använda proteasomhämmarna, MG262 och lactacystin. Våra resultat visar på att MG262 
har en direkt effekt i tillväxtplattan och hämmar tillväxten hos behandlade möss. Effekten 
är kopplad till ökad celldöd av de stamcellslika broskcellerna. Genom att blockera 
uttrycket av två regulatoriska proteiner, p53 och AIF, lyckades vi delvis rädda 
kondrocyterna från MG262-inducerad celldöd. 
Eftersom bortezomib är i kliniska prövningar på barn med cancer är det av yttersta 
vikt att undersöka om den har några biverkningar på benets utveckling och längdtillväxten 
(artikel II). Våra resultat tyder på att en klinisk relevant dos av bortezomib resulterar i 
permanent tillväxthämning, både under behandlingen och även efter en 
uppföljningsperiod på 6 månader efter sista injektionen hos möss. Bortezomib inducerar 
celldöd i tillväxtplattans stamcellslika kondrocyter, genom att aktivera flera proteiner som 
är kända för att medverka till att inducera celldöd. Dessa resultat är även i linje med vad 
vi ser i odlade biopsier från human tillväxtplatta, dvs. ökad celldöd (20%) jämfört med 
kontroll (obehandlad).  
I ett försök att rädda längdtillväxten vid behandling med bortezomib använde vi oss 
av ett syntetiskt framställt protein vid namn [Gly
14
]-Humanin (HNG) (artikel III). HNG 
har visat sig skydda från celldöd. Genom att kombinera bortezomib med HNG kan vi 
förhindra bortezomib’s negativa effekter på kondrocyterna och därmed rädda 
längdtillväxten. Viktigt nog så interfererar inte HNG med bortezomib’s anti-cancer effekt, 
vilket har bekräftats i flera olika experimentella modeller. 
Betydelse: Det är viktigt att barn kan ges nya mediciner med förbättrad 
anticancereffekt utan att orsaka allvarliga biverkningar i form av extrem kortvuxenhet, 
något som våra resultat tyder på att HNG kan förhindra. Vi rekommenderar att 
längdtillväxten övervakas och följas upp noggrant hos behandlade barn i de pågående 
kliniska prövningarna med proteasomhämmare.  
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1 FOREWORD 
 
This thesis focuses on a specific type of chemotherapy drugs called proteasome inhibitors 
(PIs), and their effects on linear bone growth. The general aim was to characterize 
whether PIs may have any eventual negative effects on chondrocytes and, in turn, induce 
bone growth impairment. Finally, an attempt was made to identify targets and therapies in 
the prevention of bone growth impairment without interfering with the desired anti-cancer 
effect of PIs. To address this, a wide range of experimental models were applied 
including chondrogenic and cancer cell lines, rat metatarsal bones, normal and genetically 
modified mice, human tumor xenograft mouse models, as well as human growth plate 
cartilage obtained from adolescent patients.          
                                                                                                                                                                                                                     
 
 
 
 
 
Stockholm, May 2013    
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2 INTRODUCTION 
The development of more successful anti-cancer agents has increased the population of 
adult childhood cancer survivors (Smith, Seibel et al. 2010). However, the recent 
advances in treating childhood cancers with new and progressively more intensive 
treatment regimens have also led to cancer survivors facing long-term skeletal defects and 
impaired bone health (Robson, Anderson et al. 1998). It has become increasingly apparent 
that children grow poorly during and after applied cancer therapy, where osteopenia and 
osteoporosis often are found in adult survivors, a condition that increases the risk for 
fractures. Many clinical studies have outlined these problems (Kirk, Raghupathy et al. 
1987; Schriock, Schell et al. 1991; Thun-Hohenstein, Frisch et al. 1992), and recently, 
experimental in vivo/in vitro studies have started to investigate the direct effects of 
chemotherapy on linear bone growth, including underlying cellular mechanisms. The 
notion of these facts make it even more important to evaluate the eventual long-term 
effects on normal bystander tissues, including linear bone growth, of new therapeutic 
approaches in childhood cancers, including possible ways to prevent them.            
 
 
2.1 LINEAR BONE GROWTH  
2.1.1 The skeleton  
Skeletal growth is one of the most fundamental tasks of childhood development, 
including an important tool for the assessment of an individual’s health status. The 
skeletal system is multifactorial in that it provides the firm framework and support to 
the body, serves to protect internal organs, is the primary storage site for minerals, and 
functions in hematopoiesis. The vertebrate skeleton is separated into two major 
subdivisions, the axial and appendicular components. The axial skeleton consists of the 
skull, spine, sternum, and ribs, whereas the appendicular skeleton defines the bones of 
the extremities. Bone formation of the skeleton is the result of two distinct processes, 
intramembranous bone formation and endochondral ossification (Kronenberg 2003). 
Intramembranous bone formation gives rise to certain flat bones of the skull, pelvis, 
scapula, parts of the mandible and clavicle, as well as the cortical dense bone of the long 
bones, and is achieved by direct transformation of condensing mesenchymal cells into 
bone forming cells (osteoblasts). The axial and appendicular skeleton develops by 
endochondral ossification through a more complex, multistep process that first requires 
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formation and degradation of a cartilage structure that then serves as a foundation for 
the developing bone. This does not only take place during skeletogenesis, but is also a 
part of the subsequent postnatal growth, remodeling, and fracture repair (Stevens and 
Williams 1999).  
 
2.1.2 Bone development - limb formation 
The formation of the cartilage model and skeletal elements begins during embryogenesis 
with the migration and subsequent condensation of immature mesenchymal cells (Fig. 
1a). The mesenchymal cells differentiate and become chondrocytes that proliferate in a 
randomly oriented fashion and deposit extra cellular matrix (ECM) rich in collagen type II 
and the proteoglycan aggrecan that serves as a template for future bones (Fig. 1b). In 
humans, condensation can be found at 6.5 weeks gestation, whereas the                     
cartilage anlagens have been detected by 8 weeks gestation (Burkus and Ogden 1984; 
Horton 2003). Comparable structures can be seen in mice at 10.5 days and 11.5 days of 
the 19 days gestation, respectively (Kaufman 1992). Members of the Sox family of 
transcription factors, mainly Sox9, are essential for cartilage formation and chondrocyte 
differentiation, and has been implicated in the production of collagen type II (Bi, Deng et 
al. 1999). When the cartilage template is formed, chondrocytes in their centers stop 
proliferating, enlarge in size (hypertrophy), and stop expressing many chondrocyte 
specific genes such as Sox9 and begin to express genes characteristic of hypertrophic 
chondrocytes, including collagen type X, VEGF, HIF-1α, and alkaline phosphatase (Fig. 
1c and d) (Iyama, Ninomiya et al. 1991; Gerber, Vu et al. 1999; Schipani, Ryan et al. 
2001). Hypertrophic chondrocytes in the mid-shaft of the bone direct the mineralization of 
the cartilage model. Coinciding with these changes, the loose mesenchyme surrounding 
the cartilage model differentiate into the perichondrium, where bone forming cells 
(osteoblasts) form the bone collar adjacent to the mid-shaft, hypertrophic region (Fig. 1c 
and d). Blood vessels, osteoclasts, as well as bone marrow, and osteoblast precursors then 
invade the cartilage model from the perichondrium and proceed to form the primary 
ossification center (Fig. 1e and f). The primary center expands towards the ends of the 
cartilage model as osteoclasts, remove cartilage ECM, and osteoblasts deposit bone on the 
cartilage remnants (Fig. 1g and h). As linear bone growth proceeds chondrocytes in the 
center of the epiphysis stop proliferating, become hypertrophic and attract vascular 
invasion along with osteoblasts forming the secondary ossification centers at each end of 
the long bones (Fig. 1i) (Kronenberg 2003). Now, in-between the primary- and secondary 
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ossification centers, at each end of the long bones, the cartilage that is left is called growth 
plate, which is the tissue responsible for linear bone growth. Growth plates are found in 
all long bones, and are established around the end of the first trimester in humans and 
around 15 days of gestation in mice (Horton 2003). Skeletal maturity occurs when the 
expanding primary center meets the secondary ossification centers, thus eliminating the 
growth plate. This process is called endochondral ossification, from where the cartilage 
template is replaced by bone that is initiated during fetal life and continues until growth 
ceases in late puberty/early adulthood.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of bone formation and growth. a, b) The initial 
condensation of mesenchymal cells and their differentiation to chondrocytes forms the 
cartilage anlagen of future bones. c) Chondrocytes in the central anlage further 
differentiate and enlarge in size (hypertrophy). Coincidently, the loose mesenchyme 
surrounding the cartilage anlage differentiates into perichondrium. d) Osteoprogenitor 
cells in the perichondrium differentiate into osteoblasts and form the bone collar adjacent 
to the mid-point of the cartilage model, which will become surrounded by the periosteum. 
This process is followed by vascular and osteoblastic invasion into the central cartilage 
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anlage (e), and cartilage is replaced by bone (formation of the primary ossification center) 
(f). This process expands toward the ends of the bone (g, h), where secondary ossification 
centers later form in the epiphyseal cartilage with formation of the mature growth plates 
(i). Illustration reprinted with permission from Elsevier Copyright (2006) and Horton WA 
from the paper “FGFs in endochondral skeletal development” by Horton WA and Degnin 
CR. Trends in Endocrinology and Metabolism 2006;20(7):341-348. 
 
 
 
2.1.3 Growth plate structure and function  
The growth plate, a transient layer of hyaline cartilage that is present only during the 
growth period is found between the epiphysis and metaphysis at each end of the growing 
long bones, and is the basic structure for endochondral ossification. The growth plate 
consists of three distinct zones: the resting zone, the proliferative zone, and the 
hypertrophic zone (Figure 2). Any imbalance in the different factors regulating 
chondrocytes in the different zones may result in impaired bone growth. It is the 
combination of chondrocyte proliferation, chondrocyte hypertrophy, and ECM production 
that is the major contributor to linear growth: each of them accounting for approximately 
10%, 60%, and 30%, respectively (Wilsman, Farnum et al. 1996). 
 
2.1.3.1 Resting zone 
The resting zone contains immature and undifferentiated chondrocytes, resting/stem-like 
cells, capable of generating new clones of proliferative zone chondrocytes (Hunziker 
1994; Abad, Meyers et al. 2002). The term “stem-like” indicate that they have the 
capacity to feed daughter cells into the adjacent proliferative layer, but are not a true stem-
cell per se with the ability to continuously divide and develop into various other kinds of 
cells/tissues. Resting/stem-like chondrocytes are nearly spherical in shape, exist as single 
cells or in pairs separated by large amounts of ECM consisting largely of collagen type II 
and proteoglycans, and they exhibit a low proliferative rate. In rabbits, it was previously 
shown that when removing the proliferative- and hypertrophic zones from the growth 
plate, leaving only the resting zone, this was enough to reestablish a completely new 
growth plate (Abad, Meyers et al. 2002). The same group also showed that these cells are 
essential for orientation of the underlying proliferative-zone columns by producing a 
growth plate-orienting factor (GPOF) (Abad, Meyers et al. 2002). These findings 
underscore the importance of the resting/stem-like chondrocytes for proper bone growth, 
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and any disturbances in their activity can therefore have severe harmful effects of 
chondrogenesis and bone growth. 
 
2.1.3.2 Proliferative zone 
Chondrocytes in the matrix-rich proliferative zone become larger in size and more 
discoid/flattened in shape, and line up in columns perpendicular to the long axis of the 
bone. These cells actively produce large amounts of ECM containing collagen type II and 
type IX, which help maintain the integrity, function, and shape of the growth plate 
(Hunziker and Schenk 1989; Nilsson and Baron 2004). The human growth plate grows 
slowly in comparison to rodents, and the rate of cell division in the proliferating cells of 
the cartilage columns is low. For example, distal femur growth rate in humans (5-8 
years of age) is 35 µm per day with a cell cycle time of approximately twenty days, 
whereas in a young rat, the growth rate is 200 µm per day with a cell cycle time of 2 
days (Kember and Sissons 1976). In the rat, there is a relatively rapid rate of cell 
division for cells in the central part of the proliferation zone (50-60 % of cells dividing 
every day), while cells at the end of the columns are dividing more slowly (5-10 % each 
day). Similar phenomenon is also seen in the human growth plate (Kember and Sissons 
1976)..Eventually, the chondrocytes in this zone lose their characteristic discoid shape 
and their capacity to divide; subsequently, they enter the zone of maturation (hypertrophic 
zone). An interesting observation is that during puberty, when the characteristic growth 
spurt is obvious, there is no evidence that the number of cells in the proliferative zone 
increases, and thus it seems likely that proliferating cells divide faster in order to produce 
the increased growth rate (Kember and Sissons 1976).  
  
2.1.3.3 Hypertrophic zone 
Growth in this zone is no longer the result of proliferation/cell division, instead the 
chondrocytes enlarge in size (hypertrophy), take on a round appearance, secrete large 
amounts of ECM rich in collagen type X, and express vascular endothelial growth factor 
(VEGF), matrix metalloproteinases (MMPs), and fibroblast growth factors (FGFs), which 
all are important for subsequent bone remodeling (Baron, Klein et al. 1994; Gerber, Vu et 
al. 1999; Haeusler, Walter et al. 2005). These cells continue to enlarge to the point where 
they have increased their intracellular volume approximately 10 times (Hunziker, Schenk 
et al. 1987). Hypertrophy is characterized by an increase in intracellular calcium 
concentration, essential for the production of matrix vesicles (small membrane-bound 
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particles that are released from hypertrophic chondrocytes), which contains large amount 
of annexins that mediate calcium uptake (Anderson 2003). The vesicles secrete calcium 
phosphatase, hydroxyapetite, and MMPs, resulting in mineralization of the surrounding 
matrix. The mineralization process together with the low oxygen tension and expression 
of VEGF attracts blood vessels from the underlying primary ossification center/primary 
spongiosum, which together are the key mechanisms for attracting bone cells into the 
hypertrophic cartilage (Gerber, Vu et al. 1999). When all glycogen stores are depleted, the 
mineralized chondrocytes lastly undergo “death” at the chondro-osseous junction, leaving 
a platform for new bone formation. There still seems to be a debate as to how 
chondrocytes are finally removed, and different theories have been proposed, such as 
programmed cell death (apoptosis) (Zenmyo, Komiya et al. 1996), or a type of aberrant 
cell death (e.g., necrosis, chondroptosis, autophagy, transdifferentiation, 
“paralysis”/”limbo” (unable to live or die)) (Roach and Erenpreisa 1996; Erenpreisa and 
Roach 1998; Meijer and Codogno 2004; Roach, Aigner et al. 2004). What is clear, 
however, is that chondrocyte removal at the chondro-osseous junction is a part of the 
normal process of bone elongation, and any disturbances might lead to defective linear 
bone growth.  
 
 
 
Figure 2. Structural organization of the growth plate cartilage. The growth plate is 
located in each end of the long bones. The hatched square on the left skeletal image is 
further clarified by the middle magnetic resonance (MR) picture that indicates the distal 
femur, knee joint, proximal tibia, and the growth plates (white horizontal line within the 
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bones indicated by arrows). The right microscopic image shows the schematic cellular 
orientation of the growth plate located between the epiphysis and metaphysis. The growth 
plate is divided into three distinct zones that represent histological and functional stages 
of chondrocyte differentiation: resting (stem-like), proliferative, and hypertrophic zones.
  
 
2.1.4 Mediators and regulation of bone growth 
Formation of the skeleton and linear bone growth are processes that are critically 
dependent on the proper homeostasis and balance between different genetic and hormonal 
factors, growth factors, environment, and nutrition, which may influence the final height 
of an individual (some of which are further explained below). Intrauterine growth in 
humans is where the most rapid growth of a lifetime takes place, with a complete fetus of 
approximately 50 cm in length produced from a single cell in only 9 months. Before birth, 
the key regulators of growth are believed to be nutrition, IGF-I and -II, and insulin, 
functioning largely independent of GH (Gluckman 1997). This is based on findings from 
both knockout experiments in mice, and in congenital GH deficiency in humans were 
birth length was only mildly diminished, whereas in congenital IGF deficiency, birth size 
was severely affected (Woods, Camacho-Hubner et al. 1996). Postnatal linear growth in 
humans is divided into three major phases: Infancy, Childhood, and Puberty (according to 
the ICP-model), which are strongly reflected by the different hormonal phases of the 
growth process (Karlberg 1987). The first phase, infancy, is characterized by a high 
growth rate from birth, with a rapid deceleration up to about three years of age. 
Childhood, the second phase, sees slow growth during the early age of childhood up to 
puberty. From birth, GH is an important modulator of longitudinal bone growth (given 
normal thyroid hormone secretion) together with the IGFs. Consequently, defects in any 
of these factors results in severe dwarfism (Rosenfeld, Rosenbloom et al. 1994; Gothe, 
Wang et al. 1999; Lopez-Bermejo, Buckway et al. 2000). The third period, puberty, is 
associated with an increased growth rate known as the pubertal growth spurt. The spurt 
itself accounts for approximately 20% of final height, then growth velocity rapidly 
decreases due to growth plate maturation in the long bones and spine, and thus, 
subsequently final height for an individual will be achieved. In other mammals, a similar 
dramatic decline in growth rate occurs, but without a superimposed pubertal growth spurt. 
Epiphyseal fusion is an active process with its own hormonal control, cellular 
mechanisms, and structural features (Perry, Farquharson et al. 2008). In both sexes, 
estrogen is the critical hormone in controlling growth plate acceleration and fusion 
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(Grumbach 2004). The general idea that bone growth stops has been believed to be 
because of growth plate fusion (Wilkins 1965). However, this concept has been 
challenged by the observations that cessation of growth occurs first, followed later by 
fusion of the growth plate (Roach, Mehta et al. 2003).  
 
2.1.4.1 Local (autocrine/paracrine) regulation of growth plate cartilage 
 
SRY (Sex determining region) Y-box 9 (Sox9): Sox9 is a critical factor for all phases of 
the chondrocyte lineage, from early condensation to the conversion of proliferating to 
hypertrophic chondrocytes, and also determines the fate of mesenchymal stem-cell (MSC) 
condensations into collagen type II-expressing chondrocytes (Lefebvre and de 
Crombrugghe 1998). Sox9 mutation causes the rare condition campomelic dysplasia, 
characterized by severe dwarfism and skeletal anomalies (Foster, Dominguez-Steglich et 
al. 1994). 
 
Runt-related Transcription Factor 2 (RUNX2): RUNX2, previously named Cbfa1, is 
important in the regulation of growth plate cartilage by promoting differentiation of 
chondrocytes into hypertrophy as well as for its role in osteogenesis (Inada, Yasui et al. 
1999). 
 
Indian Hedgehog (Ihh)/ Parathyroid Hormone-related Peptide (PTHrP) signaling: 
Ihh, produced by prehypertrophic and early hypertrophic chondrocytes, is considered 
the master regulator of chondrocyte proliferation and differentiation, as well as 
osteoblast differentiation and ossification of the perichondrium (Vortkamp, Lee et al. 
1996). Ihh binds to its receptor, patched-1 (Ptc-1), which leads to activation of the 
membrane protein, Smoothend (Smo), required for the actions exerted by Ihh on cells. 
PTHrP, expressed by periarticular perichondrium with its receptor found highly 
expressed in late-proliferating and early-hypertrophic chondrocytes, plays a crucial role 
in keeping proliferative chondrocytes in the proliferative stage (Vortkamp, Lee et al. 
1996). The orchestrated feedback loop involving Ihh and PTHrP plays key roles in 
regulating the entry and exit of cells into and out of the columnar zone. Ihh can 
stimulate the entry of resting/stem-like chondrocytes into the proliferative zone 
independent of PTHrP (Kobayashi, Soegiarto et al. 2005), or it can stimulate the 
expression of PTHrP in periarticular cells, thereby regulating the onset of hypertrophic 
 10 
differentiation. PTHrP in turn signals back to chondrocytes in the proliferative zone by 
binding to its receptor, inhibiting differentiation into Ihh‐expressing prehypertrophic 
cells, thereby shutting off the production of Ihh by maintaining these cells in the 
proliferative phase (St-Jacques, Hammerschmidt et al. 1999). The importance of this 
Ihh/PTHrP feedback loop for normal endochondral bone formation is underscored by 
the illustrations that disruption of any of the components results in abnormal limb 
development (St-Jacques, Hammerschmidt et al. 1999). 
 
Bone morphogenetic proteins (BMPs): The family of BMPs is comprised of at least 15 
members. BMP signaling is essential for endochondral ossification by promoting the 
commitment of mesenchymal cells to the chondrogenic lineage, as well as in the 
regulation of proliferation and hypertrophy of growth plate chondrocytes (Pogue and 
Lyons 2006).  
 
Fibroblast growth factors (FGFs): The family of FGFs constitutes at least 22 members 
that interact with at least four receptors (FGFR), and are major regulators of embryonic 
bone development (Ornitz and Marie 2002). FGFs are mainly produced by cells in the 
perichondrium, and act in a paracrine manner on FGFRs expressed in proliferative and 
hypertrophic chondrocytes in the growth plate. Opposite to Ihh/PTHrP and BMP 
signaling, FGFs provide essential inhibitory signals in the control of chondrocyte 
proliferation. 
 
Vascular endothelial growth factor (VEGF): VEGF appears to be a key factor for 
vascularization of the growth plate, and a critical step for successful bone formation. 
During chondrocyte hypertrophy, ECM surrounding the hypertrophic cells becomes 
calcified, which triggers the invasion of blood vessels from the underlying metaphyseal 
bone. This is preceded by the expression of VEGF in hypertrophic chondrocytes (Gerber, 
Vu et al. 1999). Thus, VEGF is an essential coordinator of chondrocyte death, 
extracellular matrix remodeling, angiogenesis, and bone formation in the growth plate. 
 
Wingless-type MMTV integration site family (Wnts): At least 19 Wnts comprise a family 
of secreted cysteine-rich glycoproteins that interact with several receptors called Frizzled 
(Fzd). Wnts are expressed in the surrounding tissue of the early mesenchymal 
condensations that will become the cartilage template of the new bone (Day, Guo et al. 
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2005). Low Wnt signaling allows for chondrogenesis and subsequent endochondral 
ossification, whereas high Wnt signaling enhances ossification of mesenchymal cells. 
 
 
2.1.4.2 Hormonal regulators of growth plate cartilage 
 
Growth hormone (GH): GH is believed to be the key endocrine regulator of linear bone 
growth, together with a coordinated network of IGFs, IGF-I and IGF-II, and their 
receptors. Enhanced GH secretion caused by a pituitary adenoma in childhood cause 
gigantism (Sotos 1996), while any defects leads to severe dwarfism (Wit, Drayer et al. 
1989; Rosenfeld, Rosenbloom et al. 1994; Lopez-Bermejo, Buckway et al. 2000). 
Systemic actions of GH are thought to be mediated by IGF-I, formerly known as 
“sulfation factor” or “somatomedin” (Salmon and Daughaday 1957), which is produced 
systemically by the liver or locally by chondrocytes (Le Roith, Bondy et al. 2001). 
Interestingly, double knockout of GHR and IGF-I results in mice that are smaller than 
single gene knockouts, indicating that GH and IGF-I co-interact positively by 
stimulating bone growth (Lupu, Terwilliger et al. 2001). However, a direct effect of GH 
in chondrocytes has been suggested, as the growth hormone receptor is detected in all 
zones of the growth plate (Parker, Hegde et al. 2007). This concept is supported by the 
finding that local GH injection into the tibia growth plate accelerated linear growth 
compared to the unilateral bone (Isaksson, Jansson et al. 1982). Furthermore, GH may 
act directly on resting/stem-like chondrocytes to stimulate proliferation, as well as 
indirectly, through IGF-I to promote chondrocyte hypertrophy (Wang, Zhou et al. 
2004). However, these observations do not discard the possibility that some of the 
effects are mediated by local production of IGF-II.  
  
Insulin-like Growth Factors (IGFs): This family includes three ligands (IGF-I, IGF-II, 
and insulin), their cell surface receptors (IGF-IR, IGF-II/[M-6-P]R, and IR), and six high-
affinity binding proteins (IGFBP-1 to -6) which prolong the half-life of the IGFs and 
modulate their bioavailability and activity (Le Roith, Bondy et al. 2001). IGF-I plays an 
important role during both embryonic and postnatal growth, indicated by severe growth 
failure in mice carrying null mutations in the IGF-I gene (Liu, Grinberg et al. 1998). IGF-
I is produced by chondrocytes in the proliferative zone, and increased expressions are 
found upon stimulation with GH, suggesting that IGF-I has a specific role in the 
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differentiation of chondrocytes through autocrine/paracrine mechanisms (Nilsson, 
Isgaard et al. 1986). IGF-I and -II receptors are expressed throughout the growth plate, 
but was found to decrease with age coincident with a period of rapid decline in growth 
velocity (Parker, Hegde et al. 2007). IGF-II was found at high levels in the growth plate, 
especially in resting and proliferative chondrocytes, suggesting a role in proliferation 
(Parker, Hegde et al. 2007). IGF-II is a positive regulator of prenatal growth; however, its 
role during postnatal growth remains unclear.  
 
Thyroid hormones: Thyroid hormones, triiodothyronine (T3, the active form of thyroid 
hormone) and thyroxine (T4, the pro-hormone) are crucial for normal bone maturation. 
They act through thyroid hormone receptors (TRs) expressed in the resting and 
proliferative zones to regulate chondrocyte proliferation, differentiation, and vascular 
invasion at the growth plate (Robson, Siebler et al. 2000). Part of these effects appear to 
be mediated by modulating local GH and/or IGF-I actions (Williams, Robson et al. 
1998).  
 
Glucocorticoids (GCs): Prolonged GC therapy in various clinical conditions is 
associated with decreased bone volume as well as growth retardation (Bello and Garrett 
1999). In contrast, familial GC deficiency is associated with tall stature (Elias, Huebner 
et al. 2000), suggesting that GC is a potent negative regulator of chondrogenesis. 
Evidence for a direct effect of GC in the growth plate came from a study in which local 
dexamethasone infusion was found to reduce tibia growth compared with the 
contralateral vehicle-injected leg (Baron, Klein et al. 1994). GC-receptors are expressed 
in the proliferating and hypertrophic zones, and GC-induced growth inhibition is most 
likely explained by reduced chondrocyte proliferation and matrix synthesis in 
combination with increased apoptosis of hypertrophic chondrocytes (Chrysis, Ritzen et 
al. 2003). 
 
Estrogens: Estrogen is the main determinant for the puberty-associated phenomena 
related to longitudinal growth and bone quality, including growth plate fusion in boys 
and girls (Grumbach 2000), probably by accelerating chondrocyte proliferation, and 
thus advancing chondrocyte senescence (exhaustion of the proliferative capacity). Much 
of the growth acceleration due to estrogen is mediated by estrogen-induced stimulation 
of the GH/IGF-I axis. The local action of estrogens in the growth plate is mainly 
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supported by the expression of the two nuclear receptors, estrogen receptor-α (ERα) and 
estrogen receptor-β (ERβ), and also by the more recently identified membrane-bound G 
protein-coupled estrogen receptor 1 (GPER1, formerly known as GPR30) (Nilsson, 
Chrysis et al. 2003; Chagin and Savendahl 2007).  
 
Androgens: Androgens also contribute to the pubertal growth spurt, although to a lesser 
extent than estrogens, by mechanisms not fully understood. Most of the androgen 
effects on linear bone growth are probably due to aromatization into estrogen in 
peripheral tissues, possibly in the growth plate as well. This hypothesis is supported by 
findings of chondrocyte expression of aromatase P450 (CYP19), which converts 
testosterone into estrogen (Oz, Millsaps et al. 2001). However, androgens may also have 
a direct effect as androgen receptor (AR) expression has been detected in rat and human 
growth plate cartilage (van der Eerden, van Til et al. 2002; Nilsson, Chrysis et al. 2003).  
 
Leptin: Leptin is a hormone secreted primarily by white adipose tissue, regulates food 
intake and body weight. Leptin deficiency in mice impairs linear bone growth, while 
treatment of these mice with leptin injections increased bone growth (Steppan, 
Crawford et al. 2000). In contrast, in the few humans described with leptin deficiency or 
leptin-receptor deficiency, skeletal growth appeared normal (Ozata, Ozdemir et al. 
1999). Leptin receptors are expressed in chondrocytes, and leptin-treatment was found 
to stimulate chondrocyte proliferation and differentiation as well as IGF-I-receptor 
expression (Maor, Rochwerger et al. 2002). 
 
2.1.4.3 Environmental factors 
Besides genetic control, many lifestyle/environmental factors including exercise, nutrition 
and medical treatments also play important roles in regulation of bone growth and 
remodeling. Adequate physical exercise and loading are important for normal bone 
growth, bone mass accumulation, and bone strength (Khan, McKay et al. 2000). 
 
 
2.2 CELL DEATH 
Cell death can occur by either of two distinct mechanisms: apoptosis or necrosis. In 
addition, autophagy is considered yet another mode of cell death, as is cytotoxicity by 
certain chemical compounds that can combine the aspects of deaths mentioned above. 
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2.2.1 Apoptosis 
Apoptosis (type I cell death), “normal” or “programmed” cell death, was first described in 
the literature in 1972 (Kerr, Wyllie et al. 1972), and the term apoptosis, from the Greek 
word for the “falling off” of leaves from trees is used to describe the process in which a 
cell actively participates in its own destructive process. Cell death is a normal 
physiological and highly controlled process that occurs during embryonic development, in 
the maintenance of tissue homeostasis, and also includes the death of differentiated 
hypertrophic chondrocytes to facilitate linear bone growth. The apoptotic program is 
characterized by certain morphological features such as cell shrinkage, loss of membrane 
symmetry (blebbing), condensation of the cytoplasm and chromatin within the nucleus, 
and DNA cleavage (biochemical hallmark of apoptosis), an irreversible event that 
commits the cell to die. Thus, organelle structures are usually preserved intact. In the final 
stages, the dying cells become fragmented into “apoptotic bodies”, which are rapidly 
eliminated by phagocytotic cells or macrophages without inducing any inflammatory 
response. On the other hand, inappropriate induction of apoptosis, either too much or too 
little, has pathological implications. Many cancer therapeutics (including PIs) exert their 
effects through initiation of apoptosis, and even cancer progression itself seems 
sometimes to depend upon a selective, critical failure of apoptosis. In mammalian cells, 
two major apoptotic signaling pathways exist, the extrinsic pathway that is dependent on 
death receptors (DRs) on the cell surface, and the intrinsic pathway, which is dependent 
on the mitochondria (Figure 3).  
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Figure 3. Extrinsic/Intrinsic apoptotic pathways. (1) Extrinsic/death receptor (DR) 
pathway: Upon death, stimuli/ligand binding by Fas to its specific extracellular DR 
(Fas/APO-1/CD95), formation of the death inducing signaling complex (DISC) takes 
place, which results in recruitment and activation of caspase-8. Caspase-8 can cleave 
effector caspases such as caspase-3, resulting in a caspase cleavage cascade to induce 
apoptosis, and thus caspase-8 is an important pro-apoptotic protein for the extrinsic 
apoptotic pathway. (2) In comparison, the intrinsic/mitochondrial apoptotic pathway 
initiates from within the cell. A number of different stimuli such as DNA damage can 
induce transcription of p53, which can modulate transcription of a number of members 
of the Bcl-2 family BH3-only proteins such as Bak, Bax and Bid, for example. These 
proteins translocate to the mitochondria where they promote the release of cytochrome c 
and/or inhibit anti-apoptotic Bcl-2/Bcl-XL. Cytochrome c then binds to Apaf-1, which 
further complexes with pro caspase-9 to form the apoptosome, promoting further 
cleavage of downstream effector caspases. FLIP, Bcl-2, Bcl-XL, survivin, and IAP are 
the key anti-apoptotic proteins within the extrinsic and intrinsic apoptotic pathways. 
Crosstalk between pathways occurs at the caspase level. Caspase-8 can cleave cytosolic 
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Bid to truncated Bid (tBid), whereby tBid promotes cell death via activation of Bax 
and/or Bak. Cleavage of effector caspases (by either pathway) results in apoptosis 
induction and its associated phenotype (DNA fragmentation, membrane blebbing, cell 
shrinkage, and the formation of apoptotic bodies). Mitochondrial dysfunction can also 
result in caspase-independent apoptosis, regulated via apoptosis-inducing factor (AIF). 
Proteins indicated in red are pro-apoptotic and those in green are anti-apoptotic. 
  
 
2.2.1.1 Extrinsic apoptotic pathway  
Activation of apoptosis is initiated by the binding of specific protein ligands to cell 
surface transmembrane DRs that will transduce pro-apoptotic signals from the 
extracellular space into the intracellular milieu (see Figure 3). The DRs consist of 6 
members: TNF-R1, Fas, DR3, DR4, DR5, and DR6, which all have an extracellular 
cysteine-rich domain, which is required for ligand binding, and an intracellular death 
domain (DD), which is required for apoptotic signal transduction (Rossi and Gaidano 
2003). When the specific ligand binds its respective DR, a trimerization of the receptor 
occurs, which is essential for the downstream apoptotic signaling events, with subsequent 
formation of the Death Inducing Signaling Complex (DISC) and recruitment of 
procaspase-8. Next, procaspase-8 is proteolytically activated to caspase-8 with subsequent 
activation of effector caspases such as caspase-3 and/or -7, leading to apoptosis by 
digestion of proteins (Thorburn 2004). The apoptotic signal can be amplified through the 
mitochondria (Luo, Budihardjo et al. 1998) or suppressed by the endogenous inhibitor, c-
FLIP, that competes with procaspase-8 for binding to the DISC (Irmler, Thome et al. 
1997). The extrinsic and intrinsic apoptotic pathways are thereby intimately connected. 
 
2.2.1.2  Intrinsic apoptotic pathway  
This pathway is induced by direct damage to the cell from a wide range of factors, such as 
cellular stress, irradiation, lack of growth factors and chemotherapeutic agents that may 
cause mitochondrial damage (see Figure 3). Mitochondria are triggered to release proteins 
into the cytoplasm, such as cytochrome c, AIF, and/or second mitochondria-derived 
activator of caspases (Smac)/DIABLO. Released cytochrome c interacts with the caspase 
adaptor molecule, Apaf-1, procaspase-9, and dATP to form the apoptosome complex (Li, 
Nijhawan et al. 1997). This complex dimerizes and activates caspase-9, which then 
promotes effector caspases, caspase-3, -6, and -7, resulting in cell death by activation of 
the executioner protein in the apoptotic cascade, Poly (ADP-ribose) polymerase (PARP). 
Cytochrome c release and subsequent activation of caspase-9 and the downstream events 
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are controlled by the Bcl-2 family of proteins, which are important in preventing and 
promoting apoptosis (Danial and Korsmeyer 2004). The pro-apoptotic protein, Bax, 
belonging to the Bcl-2 family, has been shown to play an essential role during 
intrinsic/mitochondria- mediated apoptosis where, upon activation, it translocates to 
mitochondria and causes apoptogenic protein release (Elmore 2007). Previous 
observation suggests that the ratio of Bcl-2 to Bax determines survival or death 
following an apoptotic stimulus (Oltvai, Milliman et al. 1993). 
 
Current data provide sufficient evidence to support a role for apoptosis in the growth plate 
as a developmentally normal process during bone elongation (Burdan, Szumilo et al. 
2009), including the regulation of different anti-apoptotic (e.g., Bcl-2 and Bcl-XL) and 
pro-apoptotic (e.g., Bax, Bad, Bcl-XS, and caspases) proteins (Amling, Neff et al. 1997; 
Chrysis, Nilsson et al. 2002). Interestingly, Bcl-2 was shown to be widely expressed in 
proliferative and prehypertrophic chondrocytes, but markedly decreased in late 
hypertrophic chondrocytes (Amling, Neff et al. 1997). The opposite pattern was observed 
for Bax protein expression, with undetectable levels in proliferative cells, and a 
progressive increase towards hypertrophic chondrocytes. This imbalance of anti- and pro-
apoptotic proteins, including TUNEL-positive cells, indicates that apoptosis is a process 
of normal chondrogenesis. Chrysis and co-workers further concluded that apoptosis is 
developmentally regulated during normal growth in rats by the detection of Bcl-2, Bcl-X, 
p53, Bax, and caspase-3 and -6 (Chrysis, Nilsson et al. 2002). They also reported that in 
older rats that show decreased growth rate and growth plate height, apoptosis is increased 
in terminal hypertrophic chondrocytes. The importance of Bcl-2 in the growth plate was 
further demonstrated in mice lacking Bcl-2, which showed accelerated apoptosis and bone 
growth impairment (Amling, Neff et al. 1997). Moreover, in both PTHrP knockout mice 
(Amizuka, Henderson et al. 1996) and in mice having an active mutation in FGFR3 
(Legeai-Mallet, Benoist-Lasselin et al. 1998), increased apoptosis of chondrocytes was 
demonstrated. In summary, these studies and others point to the importance of apoptosis 
for normal development and regulation of linear bone growth.   
 
2.2.2 Necrosis 
Necrosis, “accidental” cell death, is a pathological process in which the cell has no active 
role (Kerr, Wyllie et al. 1972). The cellular characteristics are swelling of cells, loss of 
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membrane integrity, and total cell lysis with subsequent provoking of an inflammatory 
response.  
 
2.2.3 Autophagy 
Autophagy (type II cell death), a type of self-degradation has been reported as the final 
fate for hypertrophic chondrocytes (Shapiro, Adams et al. 2005). The discovery of 
autophagy was first described in 1966 (De Duve and Wattiaux 1966), and the term 
autophagy in 1973 (Schweichel and Merker 1973): it is characterized by double-
membrane autophagic vacuoles (autophagosomes), which are organelles that are used for 
“eating” itself by use of its own proteins and lipids as nutrients. In 1996, Roach and 
Erenpreisa described hypertrophic chondrocytes that exhibited unusual ultramicroscopic 
structures with condensed chromatin, although the morphology was different from both 
apoptosis and necrosis (Erenpreisa and Roach 1998). Later, they observed an increase in 
the amount of both the endoplasmic reticulum and Golgi apparatus, and termed the type 
of death observed as chondroptosis (Roach, Aigner et al. 2004). This term was later 
revised by reassessment of the terminal hypertrophic chondrocytes that showed a death 
that resembled the characteristics of autophagy (Shapiro, Adams et al. 2005). Recently, 
genes known to trigger autophagy were found to be expressed in the growth plate 
(Watanabe, Bohensky et al. 2008) as well as the cartilage microenvironment, where low 
protein, glucose, and oxygen levels further support a trigger of the autophagic response.  
 
 
2.3 CHEMOTHERAPY 
The development of increasingly intense and successful chemotherapy regimens has 
appreciably produced a growing population of childhood cancer survivors (Smith, 
Seibel et al. 2010). Chemotherapy drugs can be divided into several groups based on 
how they work, their chemical structure, and their relationship to other drugs. The main 
chemotherapeutic drug classes include alkalyting agents (DNA-damaging), 
antimetabolites (interfering with DNA and RNA synthesis), anti-tumor antibiotics 
(anthracyclines, interfering with enzymes involved in DNA replication), topoisomerases 
(inhibiting of topoisomerase enzymes), mitotic-inhibitors (interfering with cell 
replication), corticosteroids/GCs (slowing growth, and killing of cancer cells), 
miscellaneous chemotherapy drugs/targeted therapies (e.g., proteasome inhibitors). The 
main aim of chemotherapy is to target cancer cells that by definition are quickly 
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growing cells with high proliferative rates. However, in children, normal cells in some 
tissues such as cartilage also grow, proliferate, and differentiate relatively fast during 
certain periods in life, and may thereby be targeted by these drugs as well. 
Consequently, skeletal defects and impaired bone health during childhood cancer 
treatment is a common problem, and its etiology is often multifactorial, resulting from 
the disease itself, the intensity and duration of chemotherapy, other types of therapies 
applied to enhance the cure, and malnutrition. It has become increasingly apparent that 
children grow poorly during and after the cancer therapy, and osteopenia and 
osteoporosis are also often found in adult survivors, leading to a higher risk for fractures 
(Schriock, Schell et al. 1991; Athanassiadou, Tragiannidis et al. 2005). Many clinical 
studies have outlined these problems, and recently, in vivo and in vitro experimental 
studies have started to delineate the effects by which these agents target chondrocytes, 
and in turn affect linear bone growth. Hence, the question arises whether the reported 
growth impairment of chemotherapy is due to a direct effect on cartilage/bone tissue, or 
via a systemic imbalance of essential hormones for bone growth (e.g., GH/IGF-I). We, 
and others have demonstrated a direct effect on growth plate chondrocytes and linear 
bone growth, without any systemic alterations by drugs such as 5-fluorouracil 
(commonly used for treatment of solid tumors), topoisomerase inhibitor, etoposide, and 
the alkylating agent cyclophosphamide (Wu and De Luca 2006; Xian, Cool et al. 2006; 
Xian, Cool et al. 2007; Zaman, Menendez-Benito et al. 2007; Eriksson, Zaman et al. 
2012). So far, any unwanted effect on linear bone growth has to our knowledge not yet 
been reported in children treated with PIs. Nevertheless, in preclinical models, we, and 
others, have reported that PIs have severe negative effects on chondrogenesis and linear 
bone growth (Wu and De Luca 2006; Xian, Cool et al. 2006; Xian, Cool et al. 2007; 
Zaman, Menendez-Benito et al. 2007; Eriksson, Zaman et al. 2012) (discussed further in 
2.4.5). In summary, it is of great importance to increase our understanding of the 
underlying cellular mechanisms involved, and finally to determine how the growth 
potential of individuals might be maintained during treatment for childhood cancers.  
 
2.3.1 Malnutrition 
Adequate nutritional intake is also essential for optimal skeletal development and 
growth in children, as the most common cause of growth retardation, worldwide, is 
malnutrition. In most cases, when food consumption is corrected, spontaneous catch-up 
growth occurs: however, reaching a final height depends upon several factors: the amount 
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of growth that is completed before starvation, the growth that is left, and the duration of 
the starvation period (Acheson and Macintyre 1958). Consequently, catch-up growth is 
not always complete, leading to growth deficits. Vitamin D and Calcium, both necessary 
for normal bone growth, are taken up in sufficient amounts by securing an adequate diet. 
The importance of vitamin D for skeletal growth has been demonstrated by vitamin D 
deficiency, leading to delay of linear bone growth, bone abnormalities, and increased 
fracture risk in adulthood (Holick 2007). Calcium is a fundamental nutrient for bone 
mineralization, formation, and maintenance of both the structure and stiffness of the 
skeleton (Bueno and Czepielewski 2008). 
  
2.3.2 Catch-up growth 
Catch-up growth may occur following remission of diverse growth-retarding conditions 
(e.g., Cushing syndrome, hypothyroidism, celiac disease, anorexia nervosa/malnutrition, 
and GH deficiency). The phenomenon of catch-up growth was first described by Prader et 
al. (Prader, Tanner et al. 1963), in which they noted an accelerated height velocity that 
exceeds the normal growth rate for the particular age. As a result, final height is 
improved, although this recovery of height may or may not be complete. Two principal 
hypotheses have been proposed to explain the mechanism of catch-up growth. Tanner 
postulates that catch-up growth is regulated by a “time tally” mechanism that exists in the 
brain that compares the actual body size with an age-appropriate set point and adjusts the 
growth rate accordingly (Tanner 1963). This neuroendocrine hypothesis has been 
challenged by recent studies, suggesting that catch-up growth is due to intrinsic factors in 
the growth plate (Baron, Klein et al. 1994; Gafni and Baron 2000). According to the 
intrinsic model, the mechanism explaining catch-up growth may be that a maximum 
number of cell divisions exist for each chondrocyte within the growth plate. Growth-
inhibiting conditions decrease chondrocyte proliferation, and when remission takes place, 
these cells have a greater proliferating potential, explaining the increased growth rate. 
However, these studies have all been performed in animals, in which the pattern of catch-
up growth is quite different from that of humans. For example, in a child who catches up, 
height velocity can be four times that of normal growth, whereas in rodents and rabbits 
the growth velocity increment is minimal (van der Eerden, Karperien et al. 2003). 
Additional studies are needed to address the process of catch-up growth in humans.  
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2.4 THE UBIQUITIN/PROTEASOME SYSTEM (UPS) 
2.4.1 Proteasome – structure and function 
In cells, two major destruction pathways exist, involving either the lysosome or the 
ubiquitin/proteasome system (UPS). This thesis focuses on the latter system.  
 
Proteasomes are large (2000 kDa), multimeric protease complexes residing inside all 
eukaryotes, archaea, and in some bacteria. In eukaryotes, they are located in the nucleus 
and the cytoplasm (Peters, Franke et al. 1994). The main function of the proteasome is 
to maintain cellular homeostasis by degrading unwanted or misfolded proteins, thereby 
making it essential for many cellular processes including cell proliferation, regulation of 
gene expression, cell death, signal transduction, and immune surveillance.   
 
In structure, the eukaryotic 26S proteasome is a cylindrical complex composed of the 
two outer 19S regulatory cap subunits (700 kDa) situated at each end of the 20S 
proteolytic core (see Figure 4). The two outer 19S regulatory subunits consist of six 
ATPase active sites, and approximately eight non-ATPase subunit ubiquitin binding 
sites: it is these structures that recognize the polyubiquitinated proteins, unfold them and 
transfers them into the catalytic 20S core were they become degraded into peptide 
fragments. The 20S proteolytic core of the proteasome is well conserved between 
species. It resembles a hollow, barrel shaped structure, consisting of four stacked 
heptameric rings composed of a total 28 subunits. The outer two rings in the stack 
consist of seven α subunits each, whose function is to maintain a "gate" through which 
proteins can enter the barrel, as well as to block unregulated access of substrates into the 
interior core. The inner two rings each consist of seven β subunits and contain the 
protease active sites that perform the proteolysis reactions. Three distinct proteolytic 
active sites within the β subunits have been identified: chymotrypsin-like (C-L, β5, 
cleavage after hydrophobic residues), trypsin-like (T-L, β2, cleavage after basic 
residues) and caspase- or peptidyl-glutamyl peptide hydrolyzing-like (PGPH, β1, 
cleavage after acidic residues) (Cardozo 1993). 
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Figure 4. The ubiquitin/proteasome system (UPS). The ubiquitination of target 
proteins is mediated by ubiquitin-activating enzyme (UAE, E1), ubiquitin-carrier 
proteins (E2), ubiquitin-protein ligases (E3), and ubiquitin-chain assembly factor (E4). 
Polyubiquitinated substrate proteins are recognized and unfolded by the 19S cap and 
then degraded into peptide fragments within the 20S catalytic core of the 26S 
proteasome. Bortezomib reversibly inhibits the C-L, β5-site of the proteasome. This 
figure is adapted with minor modifications by me with permission from: D. Chen, M. 
Frezza, S. Schmitt, J. Kanwar and Q. P. Dou, Bortezomib as the First Proteasome 
Inhibitor Anticancer Drug: Current Status and Future Perspectives. Current Cancer 
Drug Targets, 2011;11(3): 239-253. 
 
 
2.4.2 Degradation by the proteasome - Ubiquitination and targeting 
Aaron Ciechanover, Awram Hershko, and Irwin Rose’s work from the late 1970s and 
early 1980s received the Nobel Prize in Chemistry in 2004 for the identification of 
proteolytic degradation inside cells (Hershko, Ciechanover et al. 1981) and the role of 
ubiquitin in proteolytic pathways (Hershko, Ciechanover et al. 1980).   
 
Proteins destined for proteasomal degradation are first recognized and tagged with the 
76 amino acid polypeptide ubiquitin (highly conserved from yeast to mammals), which 
binds to lysine residues on the targeted protein (see Figure 4). The tagging reaction is 
catalyzed by sequential action of key ubiquitin ligases, consisting of four different sets 
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of enzymes: E1 ubiquitin-activating enzyme (UAE), E2 (ubiquitin-carrier proteins), E3 
(ubiquitin-protein ligases), and E4 (ubiquitin-chain assembly factor). In the first step of 
the ubiquitin conjugation cascade, ubiquitin is activated by E1 in an ATP-dependent 
manner. Following activation, activated ubiquitin is transferred to E2, which either 
directly shuttles ubiquitin to a protein substrate or does it in cooperation with E3. E4 
enzymes function as mediators of ubiquitin chain elongation. Once the protein substrate 
is mono-ubiquitinated, a polyubiquitin chain is formed through the same cascade as 
described above. The cooperative action of the ubiquitin ligases results in specific 
tagging and subsequent degradation of intracellular proteins. The degradation process 
within the 20S proteasome yields peptides of about seven to eight amino acids long, 
which can then be further degraded into shorter amino acid sequences and used in 
synthesizing new proteins. 
 
2.4.3 Proteasome inhibitors (PIs) 
Due to the fact that the UPS is involved in a diverse number of critical cellular processes, 
defects of various components within this complex system are associated with 
pathological disorders including malignancies, neurodegenerative diseases (e.g., 
Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis, and 
Creutzfeld–Jakob disease), and genetic diseases (e.g., Cystic fibrosis and Angelman's 
syndrome) (Ciechanover 1998).  
 
Furthermore, the importance of this cellular system has also attracted great interest into 
the development of inhibitors against it as an attractive target for therapeutic 
intervention of different human diseases such as cancer and stroke. PIs are broadly 
categorized into two groups: natural inhibitors and synthetic inhibitors. Natural product 
PIs include: linear peptide epoxyketones, peptide macrocycles, γ-lactam thiol ester, and 
epipolythio-dioxopiperazine toxin (Myung, Kim et al. 2001). Six main chemical classes 
of synthetic PIs exist: peptide benzamides, peptide α-ketoamides, peptide aldehydes, 
peptide α-ketoaldehydes, peptide vinyl sulfones, and peptide boronic acids (Myung, 
Kim et al. 2001). These agents were generally not considered for clinical development 
due to their lack of specificity and potency for the proteasome, and the fact that they 
were metabolically unstable. Most of today’s available PIs are targeted against the 20S 
catalytic core of the proteasome, thereby blocking general proteolysis, and ultimately 
resulting in the accumulation of a wide variety of proteins destined for degradation by 
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the proteasome, thus likely contributing to toxicity. To date, among all tested and 
available PIs, bortezomib (Velcade
™
) and Carfilzomib (Kyprolis
™
) have been approved 
by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma 
(Kane, Bross et al. 2003; Kortuem and Stewart 2013), and bortezomib for mantle cell 
lymphoma as well (Kane, Dagher et al. 2007). The efficacy of bortezomib as a single 
agent or in combination with other drugs is also being extensively studied in different 
types of malignancies (Cvek 2012). Currently, there are about 200 active clinical trials 
of bortezomib for various kinds of cancers listed in ClinicalTrials.gov. Several new and 
promising compounds have entered into clinical trials such as CEP-18770 (phase I), 
MLN9708 (phase I), marizomib (NPI-0052, Salinosporamide A, phase I), and ONX-
0912 (phase I) (Cvek 2012). The knowledge and interest of specific upstream inhibitors 
of the UPS aims to improve specificity by limiting protein targets within the cell, 
hopefully resulting in fewer adverse effects with similar anti-cancer activity. Novel 
targeted inhibitors of the enzymes within the UPS are in development and testing, 
including inhibitors of: UAE (PYZD-4409, PYR-41), Nedd8 activating enzyme (NAE, 
MLN4924), E3 (nutlins, R7112, MI-219, MI-43), deubiquitinating enzymes (DUBs, b-
AP15) (Cvek 2012). The work within this thesis has tested two different classes of PIs: 
the natural inhibitor lactacystin, and the two synthetic peptide boronic acids, MG262 
and bortezomib (Velcade
™
). 
 
2.4.3.1 Lactacystin 
An organic compound that is a Streptomyces lactacystinaeus metabolite that was 
discovered due to its ability to induce neurite outgrowth in a murine neuroblastoma cell 
line (Omura, Fujimoto et al. 1991). Later, Fenteany and colleagues showed that 
lactacystin (376.43 g/mol) also targets the 20S proteasome by irreversible blocking of 
all three β-subunits (Fenteany, Standaert et al. 1995), where lactonization into its active 
component, clasto-lactacystin β-lactone, is necessary for inhibition of the proteasome.   
 
2.4.3.2 MG262 
MG262 (Z-LLL-Boronate, 491.4 g/mol) is a highly potent and selective cell permeable 
synthetic peptide boronic acid inhibitor of the 20S proteasome, where it binds and 
blocks the C-L activity in the β5 subunit of the proteasome. MG262 significantly 
inhibits the growth of most cultured cells with a concentration of less than 100nM.    
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2.4.3.3 Bortezomib 
Bortezomib (Pyrazylcarbonyl-PheLeu-Boronate, 384.24 g/mol) was originally 
synthesized in 1995 and termed MG-341 (Myogenics Company). After promising 
results from in vitro and in vivo studies, it was tested in a small phase I clinical trial on 
multiple myeloma patients and then named PS-341. In 1999, Millennium 
Pharmaceuticals bought the rights to it and performed extensive clinical trials. 
Preclinical studies demonstrated that bortezomib was very potent against a broad range 
of cancer cell lines in vitro (Adams, Palombella et al. 1999) and in various animal 
xenograft models (Adams 2002). In 2003, seven years after the initial synthesis, it was 
approved in the US by the FDA with the name of bortezomib (brand name Velcade
™
) 
for treatment of multiple myeloma (Kane, Bross et al. 2003; Adams and Kauffman 
2004), and has recently been approved for mantle cell lymphoma (Kane, Dagher et al. 
2007).   
 
Bortezomib is a low molecular weight, water-soluble synthetic dipeptide boronic acid that 
shows high inhibitory potency and degree of target selectivity for the 20S core of the 
proteasome, and disassociates slowly (Adams, Palombella et al. 1999). Pharmacokinetic 
studies revealed that bortezomib quickly distributes into tissues from the plasma within 10 
minutes, where its half-life is more than 40 hours (Schwartz and Davidson 2004). 
Bortezomib is primarily metabolized through intracellular oxidative deboronation 
mediated by several cytochrome P450 isoenzymes into inactive enantiomers that are 
further processed and eliminated, mainly in the bile (66%), with the remainder excreted in 
the urine (Adams, Palombella et al. 1999). Bortezomib binds and blocks the C-L activity 
in the β5 subunit of the proteasome. Maximum proteasome inhibition occurs within 1 
hour and recovers close to baseline within 72 to 96 hours after administration (Schwartz 
and Davidson 2004). In addition, the measurement of proteasome inhibition is the 
clinical marker for a targeted effective dose and should be within the 50–80% range 
(Adams and Kauffman 2004). Because of promising results of bortezomib as an anti-
cancer drug in adults and in pre-clinical studies of pediatric cancers, clinical trials in 
children are ongoing. Recent phase I studies of bortezomib in pediatric patients with solid 
tumors or acute lymphoblastic leukemia (ALL) demonstrated that the drug is well 
tolerated with promising therapeutic activity (Blaney, Bernstein et al. 2004; Horton, Pati 
et al. 2007; Messinger, Gaynon et al. 2010; Muscal, Thompson et al. 2013). 
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2.4.4 Malignant cells vs. normal cells - side effects associated with PIs 
The most frequent adverse effects (incidence > 30%) in the patients treated with 
bortezomib include asthenic conditions (e.g., fatigue, generalized weakness), 
gastrointestinal events (e.g., nausea, constipation, diarrhea, vomiting, poor appetite), 
hematological effects (e.g., low platelet and erythrocytes counts), and peripheral 
neuropathy (Chen, Frezza et al. 2011). It has been demonstrated that malignant cells 
harbor elevated proteasome activity compared with normal cells (Arlt, Bauer et al. 2009; 
Ma, Kantarjian et al. 2009). Furthermore, expression of proteasome and mRNA levels is 
increased in malignant human cell lines compared with lymphocytes and monocytes from 
healthy adults (Kumatori, Tanaka et al. 1990). Accordingly, it seems widely accepted to 
say that cancer cells are more dependent on their proteasome activity for survival than 
normal cells. Hideshima et al. reported that myeloma cell lines or patient-derived 
myeloma cells were at least 170-fold more sensitive to bortezomib compared with 
peripheral blood mononuclear cells from healthy volunteers (Hideshima, Richardson et al. 
2001). Bortezomib has shown multiple targets in malignant cells including: i) activation 
of extrinsic and intrinsic apoptotic pathways, depending on cell type and dose, coupled 
with decreased levels of anti-apoptotic proteins; ii) suppression of the growth and survival 
factor, Nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB) signaling 
pathway; iii) inhibition of angiogenesis; iiii) induction of endoplasmatic reticulum (ER) 
stress and generation of reactive oxygen species (ROS) (Adams 2004). Thus, given the 
fact that bortezomib is able to target multiple pathways and networks important for cell 
survival, it is not surprising that normal cells may also be targeted. Cytotoxic effects of 
bortezomib on immunocompetent cells have been observed, suggesting an important role 
of the proteasome in these cells, and that the immune system may be defenseless in 
treated patients. It was recently demonstrated that bortezomib induces apoptosis in 
resting natural killer (NK) cells (Wang, Ottosson et al. 2009), and bortezomib treatment 
has been shown to enhance the susceptibility to viral infections by altering antigen 
processing (Basler, Lauer et al. 2009). PIs have also been shown to impair protein 
synthesis and induce cell death in rat neurons due to mitochondrial damage (Cavaletti, 
Gilardini et al. 2007). In pigs, chronic proteasome inhibition is associated with increased 
coronary artery oxidative stress and early arthrosclerosis (Herrmann, Saguner et al. 2007).  
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2.4.5 Proteasome inhibition and side effects on chondrocytes 
It has been reported that articular cartilage chondrocytes undergo apoptosis after 
treatment with the peptide aldehyde PIs, PSI and MG132, an effect related to induction 
of the extrinsic apoptotic pathway with CD95 and caspase-8 activation (Kuhn and Lotz 
2001). On the contrary, proteasome inhibition has also been implicated as a potential 
chondroprotective modality in rat experimental osteoarthritis by increasing intracellular 
HSP70 expression, which was able to protect the chondrocytes from OA-induced 
cytotoxicity (Grossin, Etienne et al. 2004). To date, except for our own studies, there is 
only one additional study showing a link between linear bone growth and proteasome 
inhibition (Wu and De Luca 2006). In that study, they used the peptide aldehyde 
proteasome inhibitor I (PSI), and showed that it reduces linear bone growth in cultured 
fetal rat metatarsal bones. This effect was linked to suppressed growth plate 
chondrocyte proliferation and hypertrophy/differentiation, together with increased 
chondrocyte apoptosis. They also showed that treatment with PSI in chondrocyte cell 
cultures increases the expression of β-catenin (negative regulator of chondrogenesis) 
and reduces the DNA binding of the transcription factor NF-κB (known to stimulate 
chondrogenesis). In line with this, we have recently shown that proteasome inhibition, 
by MG262 and bortezomib causes severe growth retardation both in vitro and in vivo 
(Papers I-III in this thesis). We observed growth failure to be associated with increased 
apoptosis mainly in resting/stem-like chondrocytes: in addition, detailed 
characterization of the underlying apoptotic pathways revealed that several pro-
apoptotic proteins were up-regulated (e.g., p53 and Bax) with induction of 
mitochondrial damage, whereas the anti-apoptotic proteins were down-regulated (e.g., 
Bcl-2 family of proteins). These finding underscore the importance of proper follow-up 
studies in treated children, both during and after PI-treatment.     
 
 
2.5 GROWTH RESCUING THERAPY 
Our mechanistic data in growth plate chondrocytes supports a role for both p53 and Bax 
during PI-induced chondrocyte apoptosis. In order to prevent the undesired effect on 
chondrogenesis and linear bone growth caused by PIs, we aimed to test genetic and 
pharmacological targeting against these pro-apoptotic proteins as potential growth 
rescuing therapies. However, complete characterization of the apoptotic pathways after 
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proteasome inhibition will also help us to identify the molecular players involved, and 
to be targeted, for the prevention of undesired bone growth-effects.   
   
2.5.1 Inhibition of p53 
To investigate the role of p53 during PI-induced apoptosis, a small molecule p53-inhibitor 
(pifithrin-α) was employed for suppression via the siRNA technique. Pifithrin-α has been 
shown to suppress p53-mediated apoptosis, and to protect mice from lethal doses of 
gamma-radiation (Komarov, Komarova et al. 1999), suggesting that pharmacological 
suppression of p53 may be a therapeutic approach to reduce the side effects of cancer 
treatment. Occurrence of p53-dependent apoptosis is likely to be one of the major players 
associated with side-effects in normal cells during cancer treatment (Komarova and 
Gudkov 1998), therefore, therapeutic suppression of p53 could help reduce the damage to 
normal tissues. Obviously, this approach is only applicable in tumors where p53 is 
mutated and/or absent, and the anti-cancer treatment applied is known to kill cancer cells 
independent of p53. PIs can induce both p53-dependent and independent apoptosis 
(Pandit and Gartel 2011). Accordingly, a combination of PIs and p53-inhibitors should 
therefore not interfere with the ability to induce apoptosis in p53-mutated cancers, but 
instead, rescue normal p53-dependent cells.  
 
2.5.2 Humanin 
Another approach that we used was through pharmacological inhibition of Bax, with a 
relatively new peptide called humanin. Approximately 10 years ago, humanin (MTRNR2) 
was discovered by a group in Japan (Hashimoto, Niikura et al. 2001). Humanin was 
discovered during a search for neurosurvival factors in unaffected areas of an AD 
patient’s brain. The question of the origin of endogenous humanin still needs to be 
resolved, due to two peptide isoforms of 21 or 24 amino acids being known, depending on 
cytoplasmic or mitochondrial translation respectively (Guo, Zhai et al. 2003). 
Additionally, there is still an open question whether humanin is translated in the 
cytoplasm or mitochondria, as both of them showed similar biological activity (Guo, Zhai 
et al. 2003). Humanin is also the first peptide discovered within the mitochondrial genome 
since its complete sequencing in 1981 by Anderson et al., and it is encoded by an open 
reading frame (ORF) found within the 16s rRNA gene. The synthetic analog to humanin, 
[Gly
14
]-HNG (HNG), where serine at position 14 is replaced by a glycine residue, was 
shown to increase the neuroprotective effects by 1000-fold (Hashimoto, Niikura et al. 
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2001) (Figure 5). Humanin and its analogs have shown promising therapeutic effects, thus 
so far only in experimental models, mainly in neurodegenerative diseases such as memory 
impairment (Mamiya and Ukai 2001), dementia/AD (Hashimoto, Niikura et al. 2001; 
Tajima, Kawasumi et al. 2005), and stroke (Xu, Chua et al. 2006). Humanin has also been 
shown to protect during myocardial infarction (Muzumdar, Huffman et al. 2010), and 
during conditions of oxidative stress and/or ischemia (i.e., oxygen deprivation due to 
reduced blood flow) (Bachar, Scheffer et al. 2010). Humanin levels are also known to 
decrease with age in both rats and humans, suggesting that humanin may play a role in the 
aging process (Bachar, Scheffer et al. 2010; Muzumdar, Huffman et al. 2010). Although 
all studies with humanin and its analogs show protective effects, the mechanisms by 
which they act is not yet understood. However, humanin has been shown to activate G-
coupled formyl peptide receptor like 1 and 2 (FPRL1 and FPRL2) (Harada, Habata et al. 
2004), STAT (Hashimoto, Suzuki et al. 2005), and glycoprotein 130 (gp130) (Hashimoto, 
Kurita et al. 2009). Thus, the findings above were observed in different cell types and not 
consistent for all cells, which stress the fact that different cell types may employ different 
receptors or mechanisms to respond to humanin. Humanin has shown both extracellular 
as well as intracellular rescuing activities. Extracellular activities by humanin have been 
shown by its possibility to increase insulin/IGF-I signaling assessed by AKT-1 
phosphorylation in mouse neurons (Zou, Ding et al. 2003), to be a potent insulin sensitizer 
(Muzumdar, Huffman et al. 2009), and protect neuronal cells by interacting with insulin-
like growth factor-binding protein 3 (IGFBP-3) (Ikonen, Liu et al. 2003). Humanin’s 
intracellular activities were indicated by its interaction with pro-apoptotic proteins (e.g. 
Bax, Bid, Bak and BimEL) (Guo, Zhai et al. 2003; Luciano, Zhai et al. 2005; Zhai, 
Luciano et al. 2005). The anti-apoptotic effect of humanin was specific to Bax-dependent 
apoptosis, as apoptosis by Bax-independent stimuli was not suppressed. Humanin has also 
been shown to have anti-inflammatory properties by decreasing cytokine levels, such as 
TNF-α and IL-6 (Miao, Zhang et al. 2008). Interestingly, the ubiquitin-protein ligase, 
TRIM11, was found to bind and ubiquitinate humanin for proteasomal degradation, thus 
adding another level to its regulation (Niikura, Hashimoto et al. 2003). In summary, 
humanin has shown beneficial anti-apoptotic and cell-protective properties during 
episodes of toxicity, serum starvation, hypoxia, and stress conditions, for example, both in 
vitro and in vivo in different cell-types, and possibly acts as a mitochondrial autocrine, 
paracrine and endocrine signal. 
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Figure 5. Amino acid sequence of humanin and HNG. The 24-amino acid peptide 
sequence of endogenous humanin (top), and of the synthetic peptide analog, HNG 
(bottom), where a single amino acid substitution at position 14 with a glycine (G) for 
serine (S) increases the biologic potency by ~1000-fold. 
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3 PROJECT RATIONALE 
Current treatment programs for pediatric cancers provide more than an 80% survival rate. 
However, adult survivors of childhood malignancies frequently suffer from secondary 
long-term complications after previous life-saving treatments (Oeffinger and Hudson 
2004; Oeffinger, Mertens et al. 2006), experiencing consequences of short stature, skeletal 
morbidity such as osteopenia, as well as bone fractures as well-known recorded long-term 
sequelae (Robson, Anderson et al. 1998; van der Sluis, van den Heuvel-Eibrink et al. 
2002). Increasing survival rates and progressively more intensive treatment regimens 
make it even more important to evaluate the long-term effects on normal bystander 
tissues. Despite the prevailing clinical evidence, there have been few investigations into 
the direct effects of anti-cancer agents and potential ways to rescue linear bone growth 
during treatment for childhood cancers. New therapeutic options specifically targeting 
cancer cells and limiting the toxic side effects are needed. The proteasome is a potential 
target for such a novel cancer therapy (Rajkumar, Richardson et al. 2005). 
 
During the development of a new drug to be used in clinical practice, it is important to 
investigate any potential adverse effect(s) the drug might have on normal bystander 
tissues. The proteasome is an enzyme that is central to many processes required for cell 
survival, and questions regarding complications with side effects towards normal cells 
when targeting this vital cellular system arise, especially in young individuals. In this 
thesis, the focus has been directed toward a new class of anti-cancer drugs, PIs, which are 
thought to signal a new era of novel drugs. My main investigation has been on 
bortezomib, which is routinely used in the adult clinic for hematological malignancies 
(Kane, Bross et al. 2003; Kane, Dagher et al. 2007), and is currently in clinical trials of 
pediatric cancers (Blaney, Bernstein et al. 2004; Messinger, Gaynon et al. 2010; Muscal, 
Thompson et al. 2013). However, so far, any unwanted secondary side effects on 
chondrogenesis and linear bone growth in treated children are unknown. Therefore, all my 
efforts have been directed toward finding out if there might be any potential risks for 
chondrocytes and on linear bone growth by the use of this drug, and, if so, can we prevent 
these without interfering with the desired anti-cancer effect in young, treated individuals?  
 
Often it is difficult to address the contribution of a specific drug/agent and its relative 
effect on chondrocytes and linear bone growth from clinical studies, since the disease 
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itself, the well-being of the patient, the nutritional status, and the different agents 
applied to enhance the cure, will have an effect on linear bone growth. For that reason, 
different experimental models can be of great help in trying to differentiate these effects, 
including mechanisms of action, and preventative strategies. Accordingly, we have 
employed a number of different model systems and methods to address our specific 
aims, all of which are discussed in the coming sections.  
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4 PROJECT AIMS  
 
The thesis focuses on the preclinical evaluation of proteasome inhibitor (PI) treatment and 
its effects on chondrogenesis and linear bone growth. The aims also encompassed 
characterization of new therapeutic approaches to prevent bone growth failure after 
previous life-saving treatment.   
 
 
The specific aims of the thesis were: 
 
 To investigate the effects of the non-clinically approved PIs, MG262 and 
lactacystin, on chondrogenesis and linear bone growth both in vitro and in vivo. 
 
 To investigate the effects of the clinically used PI, bortezomib, on chondrocytes, 
linear bone growth, and bone remodeling including the underlying molecular 
mechanism both in vitro and in vivo. 
 
 To explore if [Gly14]-Humanin (HNG, a 24-aminoacid synthetic anti-apoptotic 
peptide), can prevent bortezomib-induced bone growth impairment without 
interfering with the desired anti-cancer effect of bortezomib both in vitro and in 
vivo. 
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5 METHODOLOGY 
5.1 Proteasome Inhibitors (PIs):  
The drugs used and included in this thesis include Lactacystin (Sigma-Aldrich, 
Schnelldorf, Germany), and MG262 (Bimol International, SMS-gruppen), which both 
were pre-diluted in dH2O, of which the latter was diluted in DMSO for in vivo studies. 
Bortezomib (Velcade
™
, formerly known as PS-341, LDP-341 and MLM341, Millennium 
Pharmaceuticals, Cambridge, MA) was dissolved in 3.5 ml saline (0.9%) to a final 
concentration of 1 mg/ml (2.6 mM). The synthetic peptide analog of endogenous 
humanin, [Gly14]-humanin (HNG) (Sigma-Aldrich, Schnelldorf, Germany) was diluted 
in saline (0.9%) to a final concentration of 0.5 mg/ml or 1 mM. All drugs were aliquoted 
and stored at -80 ºC until use.   
 
 
5.2 MODEL SYSTEMS 
The perfect animal model and/or method might not exist, and each of them has its own 
advantages and drawbacks. It is up to the investigator to choose the best model/method to 
be used that best represents and has the best ability to determine and illustrate the features 
of the current investigation. The model/method chosen should also be assessed upon 
whether its labor, technical, and/or financial demands are properly met. 
 
5.2.1 Cell lines 
5.2.1.1 HCS-2/8 (Paper I):  
The availability of primary human chondrocytes is very limited, and therefore we chose to 
use the human clonal chondrocytic cell line, HCS-2/8. These cells derive from a well-
differentiated type of human chondrosarcoma that best resembles the in vivo-like 
phenotype (Takigawa, Tajima et al. 1989). It is well characterized and widely used to 
study chondrocyte proliferation/differentiation. The cells grow slowly, with a doubling 
time of 3-4 days, and their morphology resembles that of primary chondrocytes. 
Moreover, they maintain the important markers for a chondrocytic phenotype, such as 
collagen type II (marker for proliferative chondrocytes), and following differentiation, 
they start to express proteoglycans and collagen type X (i.e., a marker of hypertrophic 
chondrocytes), including three-dimensional nodule formation.    
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5.2.1.2 RCJ3.1C5.18 (C5.18) (Papers I, II, and III): 
In this thesis, the non-transformed clonal rat chondrogenic C5.18 cell line was generally 
used. This is a mesenchymal stem cell system that has been established through sequential 
steps of subcloning of isolated fetal rat calvaria cells (Grigoriadis, Heersche et al. 1988). 
The C5.18 cell line spontaneously and sequentially undergoes chondrocyte differentiation 
and terminal differentiation, displaying cartilage phenotypic stability without requiring 
biochemical or oncogenic transformation (Grigoriadis, Heersche et al. 1996; Lunstrum, 
Keene et al. 1999). Even though this system is based upon an in vitro situation, the 
morphology, cartilage specific histochemical markers, and the acquisition of the 
chondrocytic phenotype in this cell system is identical to the chondrogenic process that 
occurs in vivo (Lunstrum, Keene et al. 1999). These facts make it ideal and unique for 
studying chondrocytic cellular and molecular regulation, in addition to suggesting that our 
findings are relevant to the in vivo process. The C5.18 cell line was used and cultured as 
previously described (Spagnoli, Hwa et al. 2001). Briefly, after reaching confluence 
(resting phase; 4 days),
 
cells were treated with fresh Eagle’s minimum essential medium 
(MEM) alpha supplemented with 50 µg/ml ascorbic acid
 and 10 mM β-glycerophosphate. 
After 4-7 days of culture, the cells acquire markers of early chondrocytic differentiation
 
(i.e., collagen type II and proteoglycan synthesis), and progressively
 
acquire markers of 
terminal differentiation (e.g., collagen type X and alkaline phosphatase activity) at 10-14 
days of culture. The cultures were monitored over a total period of 12 days and cultures 
were supplemented with fresh MEM alpha every 3 days.  
 
5.2.1.3 Human cancer cell lines (Paper III): 
In order to verify that HNG does not interfere with the anti-cancer effect of bortezomib, 
we investigated several different human cancer cell lines with different phenotypic and 
genotypic characteristics. The cell lines include (and are further described in Paper III); 
six neuroblastoma  cell lines (SH-SY5Y, SK-N-BE(2), SK-N-AS, SK-N-SH, SK-N-DZ 
and IMR32); six medulloblastoma (MBL)/supratentorial primitive neuroectodermal cell 
lines (D283, D324 (also called DAOY), D425, D458, UW228-3, and PFSK-1), prostate 
cancer PC3 (ATCC CRL-1435), non-small cell lung carcinoma A549 (ATCC CRL-
2271), colon cancer (e.g., HCT116), breast cancer (e.g., MCF-7), and acute lymphatic 
leukemia (ALL; CCRF-CEM).  
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5.2.2 Organ cultures of metatarsal bones (Papers I, II, and III): 
In vitro cultures of both fetal (embryonic day 20 (E20)) rat metatarsal bones (Papers I- 
III), and postnatal (day 8 (P8)) rat metatarsal bones (Paper II) have been used to screen 
and characterize the local/direct effects of PIs on linear bone growth. Organ cultures, in 
comparison to cell cultures provide an environment that more closely reflects the in vivo 
situation. This in vitro model system enables maintenance of important factors, such as 
the cell-cell interactions, cell-matrix contacts, three-dimensional growth, and the 
possibility to follow linear growth over time. An advantage, though also a possible 
disadvantage not reflecting the actual in vivo situation, is the fact that these bones are 
cultured under serum-free conditions, are lacking blood supply and thereby are absent 
of the systemic factors and influence, which in turn facilitate the investigation of the 
direct effects of added drugs. Detailed description of the culture conditions and 
treatments can be found in the individual papers. Briefly, metatarsal bones were 
cultured in serum-free medium that was changed every 2-3 days, and cultured for a 
maximum of 12 days. Digital images were captured throughout the culture period, 
allowing the assessment of linear bone growth. 
 
5.2.3 Animal models 
All animal studies were performed with permission from the relevant Animal Ethical 
Board, and in strict accordance with the Swedish National Board for Laboratory Animals 
(SFS 1988:541). All efforts were made to minimize animals from suffering. 
 
5.2.3.1 Normal mice (Papers I and II): 
Evidently, time-patterning and regulation of linear bone growth are different in humans 
and rodents. For instance in humans, there is the characteristic pubertal growth spurt, 
and by the end of puberty the growth plates disappear and are remodeled into bone 
(Kember and Sissons 1976). While in rodents, closure of the growth plate does not 
occur, the growth plate persists as an inactive structure (Roach, Mehta et al. 2003). We 
used young mice that best represent the rapid growth and great growth potential as seen 
in children. Mice grow relatively quickly during the first weeks, and then slower growth 
is observed up to approximately 13 wks of age when they reach a plateau and growth is 
almost arrested. Furthermore, mice have been extensively studied with regards to both 
linear bone growth, and pharmacokinetics/pharmacodynamics of PIs. Two different 
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mouse strains were used: the inbred C57B strain, and the outbred NMRI strain, in order 
to delineate any strain-specific effects of PI treatment.  
 
5.2.3.2 Genetically modified mice (Paper I): 
For evaluation of the in vivo effect of proteasome inhibition in different tissues, we used 
a reporter mouse model for the UPS (Lindsten, Menendez-Benito et al. 2003). These 
mice express the ubiquitin
G76V
-green fluorescent protein (Ub
G76V-
GFP) that is 
constitutively targeted for ubiquitin-dependent proteasomal degradation. Tissues from 
these mice display low GFP fluorescence unless the cells fail to degrade the Ub
G76V
-
GFP protein as a consequence of functional impairment of the UPS. Low doses of the 
PI, MG262 (0.2 µmol/kg), were administered to male Ub
G76V
-GFP mice at 5 wks old. 
Mice were treated on day 1, 3, and 5, and then killed 48 hrs after the last injection, with 
tissues then removed for subsequent analyses of GFP accumulation under a fluorescent 
microscope.   
 
5.2.3.3 Tumor xenograft mouse models (Paper III): 
Most pediatric preclinical in vivo testing has involved tumor xenografts as the model. 
We implanted the tumor cells subcutaneously (sc.) in our xenograft models which have 
the advantage of being well described, fast, easy to handle, cheap, as well as allowing 
tumor-host interaction, which makes it possible to study angiogenesis. Xenograft tumor 
growth and response to therapy can be directly followed by observation and tumor 
burden evaluated by volume calculation using caliper measurement, without being 
invasive and with minimal stress to the animal. The main drawback of the xenograft 
model is the site/place of the tumor with regards to environmental cues from which the 
tumor cells actually originally originate (brains, in this case). Furthermore, in contrast to 
engrafting primary cells, human tumor cell lines have generally been cultured over 
several months to years, and there are concerns that they no longer represent the 
characteristics of the original modeled human tumor. The establishment of human 
tumors cells requires mice that are immunosuppressed, and we therefore used NMRI 
nude (athymic) mice for our study. These mice lack T-cells, but have a compensatory 
increase in natural killer (NK) cells, which can also limit tumor growth and prevent 
metastasis (Habu, Fukui et al. 1981). For all xenograft studies, animals were 
xenografted at an age of 4-5 weeks by the method described in other cited research 
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(Morton and Houghton 2007), and treatment procedures, housing, measurement of 
tumor- and linear bone growth etc., are described in Paper III. 
 
5.2.4 Human growth plate cartilage (Papers II and III): 
Most of our in vitro assays on the sensitivity of growth plate chondrocytes to apoptosis 
are obtained from rat and mouse tissues/cells. To verify our rodent results in non-
transformed human chondrocytes, we had the advantage of using intact human growth 
plate tissue. Biopsies were obtained from the proximal tibia and distal femur growth 
plates from pubertal children undergoing epiphyseal
 
surgery for different medical 
conditions (e.g., constitutional tall stature or leg length discrepancy). Growth plate 
biopsies were collected with a bone marrow biopsy needle, transferred to tubes 
containing culture medium DMEM-high glucose, and placed directly on ice. In the lab, 
biopsies were cut into ½-1 mm thick slices under an inverted microscope, transferred 
into individual 24-well plates, and cultured for 24 hrs in 1 ml of supplemented culture 
medium including the drug of interest. After the culture period, samples were fixed in 
4% formaldehyde for 24 hrs, decalcified in 10% EDTA pH 7.8 for 24 hrs. Samples were 
embedded in paraffin, cut into 4 µm thick slices, and mounted on glass-slides for further 
analyses. 
 
 
5.3 ANALYSES OF BONE GROWTH AND STRUCTURE 
5.3.1 Quantitative histomorphometrical growth plate analyses (Paper II):  
Growth plate histology (i.e., height of the growth plate, proliferative zone height, number 
of columns, number of cells per column, and size of terminal hypertrophic chondrocytes) 
was assessed by examining proximal tibia Alcian blue/van Gieson (AB/vG)-stained 
sections under a light microscope connected to a digital camera and a computer. Terminal 
hypertrophic chondrocytes were considered as the last chondrocyte in the intact lacuna 
closest to the chondro-osseus junction. All histological measurements were performed in 
the central two thirds of the growth plate by a person blinded to the experimental groups. 
 
5.3.2 Growth rate determination by Calcein labeling (Paper I): 
The use of fluorochromes is a relatively simple technique to considerably increase 
insights into the dynamics of in vivo bone formation (van Gaalen, Kruyt et al. 2010). 
Except for bone length measurement with calipers that only provides an end-point 
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measurement, we utilized fluorochrome-labeling by calcein. Calcein is a fluorescent 
marker that is incorporated into newly formed bone tissue, allowing determination of 
bone mineralization that is commonly used to evaluate bone elongation (Turner 1994). 
Calcein was injected 7 days before, and 1 day before sacrifice. Non-calcified femurs 
were subsequently embedded in blocks of methylmethacrylate and examined under a 
fluorescent microscope. The distance between the two calcein bands, which 
corresponded to the bone growth that took place over the 6 days, was determined by 
using image analyses.   
 
5.3.3 Dual X-ray Absorptiometry (DXA) (Paper II): 
To be able to follow and measure bone growth longitudinally during the in vivo 
experiment, we utilized DXA. DXA is a non-invasive procedure that is commonly used 
to determine bone mineral density (BMD) in clinical settings. This system distinguishes 
between hard tissue (bone) and soft tissue based on how these different tissues absorb 
the two low-energy X-ray beams that the machine sends out. The denser the tissue is, 
the less X-rays get through to the detector. By using two different X-ray sources rather 
than one, it greatly improves the accuracy. DXA analyses were performed on lightly 
anesthetized mice by using the Norland pDEXA Sabre and Sabre research software 
(Version 3.6; Norland Medical Systems, Fort Atkinson, Wsconsin, USA). Bone lengths 
were determined from these scans by measuring the length from the proximal part to the 
distal part of femurs. 
 
5.3.4 Radiographic imaging (Papers II and III): 
Radiographic imaging by X-ray is the true evaluation of bone structure, and was thereby 
used for evaluation of in vivo bone growth in Papers II and III. Bones contain much 
calcium which, due to its relatively high atomic number, absorbs x-rays efficiently. X-
ray analyses were performed on lightly anesthetized mice, and their backbones were 
fixed in a flat position for optimal imaging. The bones were visualized at a distance of 
1.0 m with the settings 50 kV and 2.5 mAs by employing the GE AMX-4 (GE 
Healthcare, USA). Mean bone length per animal was calculated by measuring the length 
from the proximal part to the distal part of femurs using computerized software (Sectra 
Image Display System 5).  
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5.3.5 Peripheral quantitative computed tomography (pQCT) (Paper II):  
pQCT is a useful tool for determination of bone mass, but due to the relatively high 
dose of radiation it delivers, its routine application for use in human clinical procedures 
is limited. Tomographic bone measurements were performed by using the Stratec XCT 
Research M (software version 5.4B; Norland Medical Systems), adapted especially for 
examination of small bones as previously described (Tivesten, Moverare-Skrtic et al. 
2004), using a rotating X-ray tube that moves around the object of interest at a fixed 
distance, allowing independent evaluation of parameters associated with trabecular and 
cortical bones. In our study, we evaluated trabecular BMD in the metaphyseal region of 
the tibia, and cortical BMD, and area and thickness in the diaphyseal region. 
 
5.3.6 Mechanical testing of bone strength by 3-point bending (Paper II): 
The mechanical properties of the femur shafts were tested with the 3-point bending 
method using a universal mechanical testing device (Avalon Technologies, Rochester, 
MI, USA). Each femur was compressed in the diaphyses (middle part) at a constant rate 
of 0.155 mm/s until breakdown. Mechanical parameters, including ultimate strength 
(maximal load in N) and energy absorbed by the bone tissue representing structural 
toughness (area under the load deformation curve, Nm × 10
−3
), were calculated. 
 
 
5.4 CELL VIABILITY AND DNA SYNTHESIS ASSAYS 
5.4.1 MTT-assay (Paper III): 
We used the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium (MTT) 
assay (Mosmann 1983). This method is suitable to assess cell viability, proliferation or 
toxicity. This in vitro model system of measuring metabolic/mitochondrial activity of 
viable cells is widely used for screening purposes of drug activity, and well suited for 
defining interactions between drugs when having many different cell-types and drugs to 
analyze. It is non-radioactive, convenient (i.e., performed entirely in a microplate), 
quantitative, and allows samples to be analyzed rapidly and simultaneously. The 
principle of this method is the cleavage of the tetrazolium salt by the mitochondrial 
“succinate-tetrazolium reductase” that is active only in viable cells to a colored water-
insoluble formazan salt, which must be solubilized before spectrophotometric 
measurement. After its solubilization, the formazan can easily and rapidly be 
quantitated in an ELISA reader. However, one has to keep in mind that during in vitro 
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culture conditions, changes in pH and nutrients in the medium might also affect to the 
metabolic state of the cells and thus give variation in the final readout. Briefly about the 
MTT test, cells were cultured and treated in a 96-well microplate before incubation with 
MTT solution for 2 hrs (viable cells convert MTT to a water-insoluble formazan dye), 
followed by solubilization of the formazan by acidic isopropanol, and quantitation of 
the colored product by an ELISA reader (spectophotometrically at 595 nm).     
 
5.4.2 5-bromo-2´-deoxyuridine (BrdU) labeling (Paper II):  
To study DNA synthesis in vivo, we employed the BrdU labeling technique. BrdU 
labeling was developed as an alternative approach for determining the proliferative 
index of tumors (Hoshino, Nagashima et al. 1989), and was introduced for studying cell 
proliferation in chondrocytes in 1993 (Farnum and Wilsman 1993). This technique 
offers the advantage of studying cell proliferation in individual cells. BrdU is a synthetic 
nucleoside (modified uridine), and an analog to thymidine. The principle underlying this 
method is the incorporation of BrdU into newly synthesized DNA of replicating cells 
during the S phase of the cell cycle (i.e., before cellular division into 2 daughter cells), 
substituting for thymidine during replication. This method of assessing cell proliferation 
has the advantage over the traditional method of 
3
H-thymidine incorporation, in that it 
does not require handling of radiolabeled material, it is reliable, fast, and susceptible for 
quantification. However, one should also keep in mind that this method is also 
associated with some cell-toxicity and teratogenicity, and may not exclusively detect 
dividing cells, but also cells undergoing DNA repair: it is also noted that BrdU can 
increase proliferation and decrease differentiation by itself (Taupin 2007). BrdU-
solution was intraperitoneally (ip.)-injected twice into mice at 16, and 2 hrs before 
autopsy. To enable quantification of the BrdU-incorporated, paraffin-embedded tissue 
sections were incubated with a BrdU-specific monoclonal antibody, followed by an 
FITC-conjugated secondary antibody, and then counterstained with DAPI. The number 
of BrdU-positive (FITC, green color) chondrocytes per growth plate was determined by 
digital automatic cell counting as described below.   
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5.5 CELL DEATH ANALYSES 
5.5.1 TUNEL assay (Papers I, II, and III):  
The terminal deoxynucleotidyl transferase (TdT)-metiated dUTP nick-end labeling 
(TUNEL) method (Gavrieli, Sherman et al. 1992) was utilized for quantification of 
apoptosis in growth plate chondrocytes obtained from animals, cultured metatarsals, and 
human growth plate tissues. The TUNEL assay has been further optimized for use in 
growth plate tissue in our laboratory (Chrysis, Nilsson et al. 2002). Briefly, proteinase K 
digestion was reduced from 20 min as recommended by the manufacturer to 5 min, and 
the concentration of enzyme was reduced from 20 ng/ml to 10 ng/ml, in order to 
minimize false positive detection of apoptotic cells. Thus, this protocol was undertaken 
in all of the studies. The assay works on the principle that nuclear DNA strand breaks 
(single or double) that occur during apoptosis can be identified by labeling the free 3’-
hydroxyl (OH)-termini. Biotin-labeled nucleotides, dUTP, are polymerized to these 3’-
OH groups in a reaction catalyzed by the TdT enzyme. The incorporated biotin-labeled 
nucleotides were then detected by a streptavidin-conjugated secondary antibody (Alexa 
Fluor-546) before mounting in DAPI-containing media. The number of TUNEL-
positive chondrocytes in relation to the total cell number per growth plate was 
determined by digital automatic cell counting as described below. This is a fast, 
relatively sensitive, and quantitatible method. It must be kept in mind that the TUNEL 
assay may also detect DNA damage associated with non-apoptotic events such as 
necrotic cell death due to extensive DNA degradation induced by exposure to toxic 
compounds, for instance (Ansari, Coates et al. 1993), and it has also been reported to 
stain cells undergoing active DNA repair (Kanoh, Takemura et al. 1999). To distinguish 
apoptosis from necrosis, we performed additional analyses that included the expression 
of pro-apoptotic proteins, including active/cleaved caspases and PARP, the cell death 
ELISA, and studies of mitochondrial damage as discussed below.     
 
5.5.2 Cell death ELISA (Paper I):  
For quantification of apoptosis in cultured chondrocyte populations, we used the 
commercially available Cell Death ELISA kit. This immunoassay detects cytoplasmic 
low molecular histone-associated DNA fragments (mono- and oligonucleasomes) of 
apoptotic cells. This assay is based on the fact that DNA fragmentation without loss of 
the plasma membrane integrity is the hallmark of apoptosis. The test principle is a one-
step sandwich immunoassay, were cells first are lysed, centrifugated and an aliquot of 
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the supernatant (DNA, singel- and double- stranded) is transferred to a streptavidin-
coated 96-well microplate, an addition of monoclonal antibodies is made (anti-histone 
biotin labeled and anti-DNA peroxidase conjugated), and the sample is incubated with 
peroxidase substrate before determining the amount of colored product 
spectrophotometrically. This method is quantitative, convenient (non-radioactive) and 
reproducible, also allowing a large sample number. Further, the antibodies in the kit are 
not species-specific and can thereby be used for a wide variety of species. Moreover, 
this method can also measure necrosis, by using the supernatant where the 
oligonucleasomes will be released into: thus, the assay provides the ability to 
distinguish from apoptosis and necrosis. Accordingly, under our experimental 
conditions we excluded the occurrence of necrosis since no mono- or oligonucleasomes 
were present in the supernatant of cell cultures. 
 
5.5.3 Caspase-3 fluorometric assay (Paper I):  
Activation of caspases (cysteine proteases) plays a key role in mediating the early stages 
of apoptosis. The activation involves specific proteolyses of individual caspases. We 
chose to analyze the activity of the executioner caspase in the apoptotic cascade, 
caspase-3, by using the specific peptide substrate, DEVD, conjugated with a fluorogenic 
7-amino-4-methylcoumarin enzyme, which can be detected fluorometrically following 
cleavage and release. Fluorescence values were converted to picomoles of AMC release 
by using a standard curve generated with free AMC, and the maximum rate of AMC 
release (pmol/min) was then estimated for each sample. This assay is described to show 
proportional caspase-3 activity to the percentage of apoptotic cells.  
 
5.5.4 Analyses of mitochondrial membrane potential (Paper II):  
To assess loss of the mitochondria membrane potential (ΔΨm), which is indicative of 
apoptosis, we used tetramethylrhodamine (TMRE) ethyl ester to quantify the time-
dependent damage of mitochondria after drug treatment (Ehrenberg, Montana et al. 
1988). TMRE is a cell permeable, positively-charged, red-orange dye that rapidly 
accumulates in active mitochondria due to their relative negative charge. It also exhibits 
low cytotoxicity, and is relatively photostable with low tendency to bind other intra-
cellular organelles. When the ΔΨm collapses in apoptotic cells, mitochondria fail to 
incorporate TMRE that become dispersed into the cytoplasm, and cellular fluorescence 
drops dramatically. This event can easily be detected by fluorescence microscopy or 
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quantified by flow cytometry. This technique can distinguish between healthy/vital 
cells, and the ones transitioning into an apoptotic state, as further discussed in Paper II. 
 
5.5.5 Digital automatic cell counting (Papers I, II, and III):  
Quantification of the number of proliferative and apoptotic cells of in vivo/in vitro 
treated growth plates/bone rudiments, was performed respectively by this method. 
Digital images of BrdU-positive cells (FITC, green color) or TUNEL-positive cells (by 
Alexa-546 antibody, red color) were captured using an Olympus DP70 digital camera. 
For each visual field to be quantified, three images were captured: a phase-contrast/light 
image, a Dapi image (detection of all cells, emission at 449 nm, blue color), and an 
FITC (emission at 530 nm) or Alexa-546 (emission at 573 nm) image. Automatic 
counting was then performed using Image-Pro
®
 Plus software (Media Cybernetics Inc, 
Bethesda, USA) within the growth plate (containing resting, proliferative, and 
hypertrophic zones). It was identified based on the light image, and the selections were 
applied to the corresponding Dapi- and FITC or Alexa-images. The percentage of 
positive cells was calculated as the ratio of bright objects in the FITC (proliferation)- or 
Alexa-546 (apoptosis)-image over the total number of bright objects in the 
corresponding Dapi image. 
 
 
5.6 DETERMINATION OF PROTEIN EXPRESSION 
5.6.1 Immunohistochemistry (IHC) (Papers I, II, and III): 
The procedure utilizing specific antibodies to identify, localize, and to a certain extent, 
quantify protein expression in the cells of a tissue section is referred to as IHC. IHC was 
utilized to detect the expression of different proteins (antigens) in formalin-fixed growth 
plate- and tumor tissue sections. Furthermore, cartilage-tissue sections, specifically 
obtained from in vivo studies are difficult to work with since they easily detach from the 
slides. Consequently, we therefore used saline-coated Superfrost +/+ glass-slides, which 
improved the attachment of the tissue to the slides. Fixation of tissue is an important step 
before subsequent analyses to preserve the cellular components and proteins intact. 
Cross-linking of proteins by formaldehyde may mask their binding-sites (epitopes), 
making it inaccessible to detection antibodies, which could result in false-negative results. 
To minimize false-negativity, the step of antigen-retrieval was added for all stainings. 
Antigen-retrieval was, in our case, achieved either by heating of the tissue in citrate buffer 
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(pH 6.0) for 15 min at 93-98°C, or by enzyme treatment. Furthermore, antigen-retrieval 
enhances the sensitivity of the immunostaining procedure, making it possible to decrease 
the concentration of the primary antibody, and thereby decrease the risk for non-specific 
staining (false-positivity). Before the addition of primary antibody, sections were 
incubated using normal serum from the host of the secondary antibody to reduce 
unspecific staining. The next step of choosing the antibody with greatest specificity and 
sensitivity against the particular antigen in the specific specie of interest is probably the 
most important issue connected with IHC, and it requires proper controls to be included in 
order to support the validity of the staining and identify experimental artifacts. 
Appropriate controls to be included are tissue samples that are known to express (or not 
express) the protein/epitope of interest. A negative control can also be obtained by pre-
incubation of the primary antibody with the appropriate immunogen, replacement of the 
primary antibody with non-immune immunoglobulin of the same isotype (when using 
monoclonal antibodies), and/or by omitting the primary antibody. Detailed description for 
each protein is further described in the Material and Method section of the individual 
papers. 
 
5.6.2 Western Immunoblot (Papers I, II, and III): 
This technique is well-established, reproducible, allows separation of proteins by their 
molecular weight, and offers the ability to quantify the expression level of proteins. We 
applied this technique to study the expression levels of both anti-apoptotic (e.g., Bcl-2, 
Bcl-XL) and pro-apoptotic (e.g., Bax, Bcl-XS, AIF, caspases, and PARP) proteins, 
including the transcription factor and its regulatory protein, p53 and Mdm-2 
respectively, in the cell extracts. Loading of equal protein amounts were based on 
quantitation using the Bradford assay (Bio-Rad Laboratories AB, Sundbyberg, Sweden). 
Proteins were separated on Tris-HCl or gradient acrylamide gels, and then transferred 
onto a Hybond-P polyvinylidene difluoride-transfer membrane, which allows detection 
of low protein levels (nanogram). Blocking of non-specific binding before incubation 
with primary antibody was achieved by placing the membrane in a dilute solution of 
protein: in our case, we always used 5% non-fat dry milk. The secondary antibodies 
used were linked to horseradish peroxidase (HRP) enzyme that will cleave the added 
chemiluminescent agent, the reaction product emitting light in proportion to the amount 
of protein, creating an image (dark band) of the antibodies bound to the blot. The 
resulting bands were confirmed by comparing the size of the protein in the cell extract 
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with known molecular weight markers. The densities of the protein-bands of interest 
were analyzed in relation to the house-keeping gene (GAPDH) to evaluate the relative 
amount of protein between samples. Finally, the extensive data in the literature 
concerning Western Immunoblotting and on the regulation of the different proteins were 
very useful for validation of our findings. 
 
 
5.7 BLOOD ANALYSES 
5.7.1 Proteasome activity analyses (Papers I, II, and III): 
Proteasome activity was measured in whole blood collected at different time-points 
from treated mice. Blood was collected in tubes containing Heparin (100IE/KY/ml, 
LEO Pharma, Malmö, Sweden), and chymotrypsin-like (C-L, subunit β5) proteasome 
activity was measured using the synthetic fluorometric substance method (Lightcap, 
McCormack et al. 2000). Briefly, the assay involves hydrolysis of exogenous added 
LLVY-AMC by the chymotrypsin-like activity of the 20S proteasome. AMC is a highly 
fluorescent molecule, and its release was measured in a spectrophotometer. This assay 
offers a unique method of measuring proteasome activity that is sensitive, accurate, and 
reproducible. In addition, the measurement of proteasome inhibition is the clinical 
marker for a targeted effective dose, and it should be in the 50-80% range (Adams and 
Kauffman 2004). 
 
5.7.2 Serum IGF-I levels (Papers I, II, and III):  
To investigate if there was any interference with the IGF-I system in treated mice, and 
try to delineate if the observed bone growth impairment was more a systemic or local 
effect, serum IGF-I levels were analyzed. Serum concentrations of IGF-I were measured 
by radioimmunoassay, using a commercially available kit (IGF-R20) purchased from 
Mediagnost, Tuebingen, Germany. The sensitivity of the assay is 0.02 ng/mL. The assay 
was performed following the instructions from the manufacturer with the exception that 
a sample volume of 3 µL was used, based on previous experiences. All samples were 
analyzed in duplicate.  
 
5.7.3 Analyses of bone biomarkers (Paper III): 
To assess the activity of osteoblasts (bone formation) and osteoclasts (bone 
degradation), a commercial sandwich enzyme-linked immunosorbent assay (ELISA) 
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was utilized according to the manufacturer instructions for quantification of serum 
levels of procollagen type 1 N-terminal (PINP) and collagen type 1 cross-linked C-
telopeptide (Ctx) respectively. The propeptide, PINP is released into the blood 
circulation during bone formation (collagen I synthesis), and is the most sensitive and 
specific marker for measurement of bone formation (Hale, Galvin et al. 2007). On the 
contrary, during osteoclastic bone resorption, Ctx is one of the degradation products of 
collagen type I. Briefly about the assay, a microtiter plate is coated with a capture 
antibody, and a sample is added before the addition of the detecting antibody that will 
bind the antigen (PINP or Ctx) in the sample. Thereafter, an enzyme-linked secondary 
antibody is added that binds the detecting antibody, and finally the chromogen that will 
be converted by the enzyme into a color that is quantified spectrophotometically is 
added. 
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6 RESULTS 
6.1 EFFECTS OF PROTEASOME INHIBITION ON CHONDROGENESIS 
AND LINEAR BONE GROWTH (PAPERS I AND II) 
 
Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in 
Chondrocytes Causing Severe Growth Retardation in Mice (Paper I) 
 
 In this study, we mostly focused on the non-clinically used PI, MG262. By using the 
transgenic reporter mouse model for the UPS, Ub
G76V
-GFP mice (Lindsten, Menendez-
Benito et al. 2003), we show that systemic administration of a clinically relevant dose of 
MG262 (0.2 µmol/kg), tissue-specifically impairs the UPS in growth plate chondrocytes. 
The impairment of the UPS was accompanied by the induction of chondrocyte apoptosis 
in growth plate cartilage of treated mice. Furthermore, this effect resulted in severe linear 
bone growth impairment, observed both 48 hrs, as well as 45 days post treatment with 
MG262, compared to vehicle-treated animals. The bone length differences (femur and 
tibia) after the 45 day follow-up period was not as striking as 48 hrs after the last 
injection, suggesting that some catch-up occurred, although this 45-day follow-up period 
was not enough to fully catch-up in growth, and we do not know what happens beyond 
this period. 
 
The underlying mechanistic studies revealed that MG262-induced growth failure was 
mainly caused by a severe thinning in the height of the resting zone, which was followed 
by chondrocyte apoptosis of the resting/stem-like and proliferative chondrocytes. Caspase 
inhibitory experiments in organ cultures of metatarsal bones and human- and rat 
chondrocytic cell lines confirmed that MG262 triggered both caspase-dependent and 
independent apoptosis of chondrocytes. Accordingly, protein expression of the 
transcription factor, p53, was also found to be increased in growth plate cartilage of 
MG262-treated mice. In addition, the regulator of caspase-independent apoptosis, 
apoptosis inducing factor protein expression, also appeared to be highly up-regulated in 
chondrocytes after MG262 treatment, both in vitro and in vivo. 
 
Suppression of p53 expression by employing the siRNA technique resulted in a 35% 
decrease in MG262-induced chondrocyte apoptosis. This finding supports a role for p53 
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during PI-induced chondrocyte apoptosis. Furthermore, in support of a role for AIF-
mediated chondrocyte cell death, suppression of AIF by siRNA decreased apoptosis of 
chondrocytes by 41%. These data support an important role for the UPS in growth plate 
chondrocytes, and by impairing this system, it results in deleterious effects on growth 
plate chondrocytes, followed by growth impairment.  
 
 
Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone 
Growth in Young Mice (Paper II) 
  
In this study we extended our investigations to the clinically used PI, bortezomib that is 
currently in clinical trials of pediatric cancers (Blaney, Bernstein et al. 2004; Messinger, 
Gaynon et al. 2010; Muscal, Thompson et al. 2013). However, so far, any undesired 
secondary side effects in fast-growing individuals have, to our knowledge, not yet been 
described. Because of the alarming data of the non-clinically used PIs on chondrogenesis 
and induction of bone growth impairment from us and others (Wu and De Luca 2006; 
Zaman, Menendez-Benito et al. 2007; Zaman, Fadeel et al. 2008), we decided to elucidate 
any potential risks of bortezomib treatment on linear bone growth, and bone metabolism, 
including the underlying molecular mechanisms. The studies were performed both in 
vivo, in two different strains of young mice (which best represents the rapid growth of a 
child), and in vitro, in cultured metatarsal bones and a chondrocytic cell line. Finally, we 
also used pubertal human growth plate cartilage to assess and verify the toxicity of 
bortezomib. 
 
Our results indicate that bortezomib efficiently blocks the UPS, with a similar degree of 
proteasome inhibition as seen in treated humans, that is to say, within the 50–80% range 
(Adams and Kauffman 2004). By using a clinically relevant dose of bortezomib (1 
mg/kg) along with a similar dosing regimen as in the clinic, we confirmed that one 2-
week cycle (2 injections/wk) causes permanent growth failure in treated mice, when 
followed for up to 6 months post-treatment. This effect was mainly due to induction of 
apoptosis in resting/stem-like chondrocytes. Previous studies suggest that it is the 
resting/stem-like cells that influence the growth plate structure and function (Gafni, 
Weise et al. 2001; Schrier, Ferns et al. 2006), and that this cell population serves as the 
pool for generating the columnar clones of the underlying proliferative zone (Abad, 
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Meyers et al. 2002). Together, these studies indicate the importance of the resting/stem-
like chondrocytes for maintenance of the normal growth potential and thus, any 
disturbances and/or depletion of it might therefore result in incomplete growth. 
Treatment with bortezomib in fetal and postnatal cultured rat metatarsal bones resulted 
in a dose-dependent growth inhibitory effect. Interestingly, bortezomib treatment for 
only 24 hrs in fetal metatarsals was enough to permanently inhibit bone growth, further 
suggesting irreversible growth failure. To identify what cells in the metatarsal bones 
that were targeted, we analyzed the bones by using the TUNEL method. Bortezomib 
dose-dependently increased chondrocyte apoptosis, an effect mainly observed in 
resting/stem-like chondrocytes. Metatarsal bones were also stained with Alcian 
Blue/van Gieson (AB/vG) to detect changes of matrix components such as 
glucosaminoglycans and collagens. Indeed, bortezomib decreased the levels of matrix 
components, indicated by the low levels of AB/vG-staining. We further confirmed our 
results in cultured human growth plate cartilage, which was found to be highly sensitive 
to bortezomib after 24 hrs of treatment. Again, mainly the resting/stem-like 
chondrocytes, and to some extent also the early proliferative chondrocytes, were 
targeted, as quantified by the TUNEL method.  
 
Our data support a local action of PIs, selectively targeting resting/stem-like growth 
plate chondrocytes, leading to decreased bone growth. This concept is supported by the 
findings in the Ub
G76V
-GFP mouse model, and measurement of serum IGF-I levels that 
were not different from vehicle-treated mice, together with the growth inhibitory effect 
in cultured metatarsal bones.  
 
The sensitivity of chondrocytes to bortezomib treatment was further verified in the rat 
chondrocytic cell line, C5.18, by utilizing the cell viability assay, MTT. The cells were 
treated for 24 hrs and 48 hrs with bortezomib (0-100 nM), which resulted in a time- and 
dose-dependent decrease in cell viability. Again, the resting/stem-like cell population 
was found to be the most sensitive one, in contrast to both proliferative- and 
hypertrophic chondrocytes. 
 
In an attempt to delineate the underlying molecular mechanisms regulating bortezomib-
induced apoptosis, protein expression profiles (using the Western immunoblot 
approach) of several pro- and anti-apoptotic proteins were investigated in resting/stem-
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like C5.18 chondrocytes. These cells were exposed to bortezomib (1000 nM) for 3, 6, 
12, and 24 hrs. Our results indicated that bortezomib induced early activation of p53 and 
Bax, as early as 3 hrs after treatment, suggesting key roles for these proteins in the 
regulation of bortezomib-induced chondrocyte apoptosis. We also observed subsequent 
cleavage of caspases (-9, -8, and -3), and finally also of poly-ADP-ribose polymerase 
(PARP) in exposed chondrocytes.  
 
Skeletal morbidity such as osteopenia and osteoporosis, including increased risk for bone 
fractures are common long-term side effects associated with childhood anti-cancer 
treatment (Siebler, Shalet et al. 2002). However, the impact of PIs on bone metabolism 
and bone strength in children are still unknown. To investigate this, we performed 
analyses of serum bone biomarkers, tomographic trabecular, and cortical bone 
measurements (by pQCT), and mechanical bone strength assessment (by 3-point 
bending test) in treated mice. Our results showed no significant effects of bortezomib on 
the bone biomarkers (PINP and Ctx), and neither on BMD, nor on bone biomechanical 
properties, such as cortical content, cortical thickness or bone strength. Previous studies 
have shown that PIs such as proteasome inhibitor-1, epoxomicin and bortezomib may 
enhance bone formation and BMD in 5-week-old Swiss ICR white mice (Garrett, Chen 
et al. 2003) and in 7-week-old C57B/6 mice (Mukherjee, Raje et al. 2008). Moreover, a 
recent study provides convincing and promising results of bortezomib on bone formation 
through stimulation of vitamin-D receptor signaling (Kaiser, Heider et al. 2013). 
Bortezomib has also been shown to suppress osteoclast activity (von Metzler, Krebbel et 
al. 2007) and increase osteoblast activity (Zangari, Esseltine et al. 2005) by activating 
Runx2 (Mukherjee, Raje et al. 2008) or inhibiting Dickkopf-1 (DKK1), an inhibitor of 
osteoblast function (Oyajobi, Garrett et al. 2007). However, bortezomib had no effect on 
femur BMD in a myeloma model of 15-week-old CB.17/Icr-SCID mice (Pennisi, Li et 
al. 2009), which is in line with our data. These conflicting results may suggest that 
regulation of mouse bone remodeling by the UPS is influenced by age, mouse strain, 
dose, duration of treatment, and/or immune function. Furthermore, we did not observe 
any positive effect of bortezomib treatment on bone strength when biomechanical testing 
was performed. Bortezomib might therefore not offer the same level of benefit to bone 
health in fast growing individuals as earlier reported in adults with multiple melanoma 
(Zangari, Terpos et al. 2012). 
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6.2 PREVENTIVE STRATEGIES TO RESCUE BONE GROWTH IN PI-
TREATED INDIVIDUALS (PAPER III) 
 
Humanin prevents bortezomib-induced bone growth impairment without interfering 
with the desired anti-cancer effect (Paper III) 
 
The present study was designed to investigate the potential for HNG to rescue from 
bortezomib-induced bone growth impairment without interfering with the desired anti-
cancer effect of bortezomib. To test this, we applied an array of different in vivo and in 
vitro models, including human tumor xenograft models of childhood neuroblastoma 
(NBL) and medulloblastoma (MBL), cultures of human growth plate cartilage, fetal rat 
metatarsal bones, and chondrogenic- and cancer cell lines.  
 
First we used the organ culture model of fetal rat metatarsal bones as a screening tool to 
assess any rescuing effect by HNG from bortezomib-induced bone growth impairment. 
Our results indicate a partial rescue of metatarsal bone growth, when combining HNG 
(100nM) with bortezomib (25nM). This promising result led us to further verify if this 
was also true in vivo, with the aim to also rule out any potential interference of HNG with 
the anti-cancer effect of bortezomib. To test this, young nude mice were first established 
with either NBL or MBL childhood tumors before receiving treatment with either one 2-
week cycle (2 injections/wk) of bortezomib, HNG, the combination of HNG/bortezomib, 
or the vehicle. Our results indicate that intravenous (iv.) injections of bortezomib (0.8 
mg/kg) efficiently blocked the proteasome (approximately 60%), an effect that was not 
disturbed by the addition of HNG. However, intraperitoneal (ip.) injections of bortezomib 
(1.0 mg/kg) resulted in a less efficient proteasome inhibition in these mice. Despite this, 
bortezomib treatment resulted in significant bone growth failure, irrespective of 
intravenous or intraperitoneal administration. Combination treatment with HNG could 
almost completely rescue bone growth, close to the growth rate observed in vehicle-
treated mice.  
 
Histomorphometrical analyses of the mouse growth plates revealed that combination 
treatment with HNG could restore growth plate height to a similar level as observed in 
vehicle treated mice. This rescuing effect was mainly due to a prevention of resting/stem-
like chondrocyte apoptosis. We also confirmed our observations in cultured human 
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growth plate cartilage, where HNG prevented bortezomib-induced chondrocyte apoptosis 
to a similar extent as seen in vivo. The chondrocyte rescuing effect of HNG was coupled 
to a suppressive effect of the pro-apoptotic proteins, Bax and the downstream executioner 
protein, PARP. Our data are in line with previous studies in other cell types where 
humanin and its analogs were found to bind Bax, preventing its activation, and thereby 
protect the cells from apoptosis (Guo, Zhai et al. 2003; Zhai, Luciano et al. 2005). An 
interesting observation that we made, was that bortezomib increased Bax accumulation in 
chondrocytes, but not in human NBL cells, suggesting that the chondrocyte rescuing 
effect of HNG might be linked to a Bax-dependent effect.    
 
The key-question if administering HNG to individuals with cancer is the risk of any 
potential interference with the anti-cancer effect of bortezomib, and hence, a rescue of the 
tumor cells. To investigate this we used several different human NBL and MBL tumor 
cell lines, including tumor cells from some of the most common human cancer diagnoses 
(i.e., lung, prostate, colon, and breast cancer), and also the human tumor xenograft mice 
models of NBL and MBL. Our in vivo data demonstrate that HNG does not diminish the 
anti-cancer effect of bortezomib, but instead potentiates it. Interestingly, HNG by itself 
showed an anti-tumor effect as documented with the highest HNG concentration tested in 
three tumor cell lines, as well as in the two different NBL tumor xenograft experiments, 
where the effect was linked to decreased angiogenesis and increased tumor-cell apoptosis. 
Our in vitro and in vivo result also confirms an anti-cancer effect of bortezomib that is in 
line with previous reports (Brignole, Marimpietri et al. 2006; Hamner, Dickson et al. 
2007; Yang, Jove et al. 2012). We observed a clear delay of tumor growth in response to 
bortezomib, but no apparent evidence of tumor regression, also consistent with previous 
reports (Michaelis, Fichtner et al. 2006; Houghton, Morton et al. 2008). 
 
 
 
 
 
 54 
7 CONCLUDING REMARKS  
Using an array of different in vitro and in vivo models of chondrogenesis and linear bone 
growth, the current study revealed that clinically relevant doses of PI-treatment 
specifically target the growth plate and damage normal chondrogenesis, which in turn is 
reflected by bone growth failure. Histology and cellular analyses further demonstrated 
pronounced reduction of growth plate height, associated with a suppressed height of all 
zones in the growth plate, reduced size of terminal hypertrophic chondrocyte, and we also 
observed that bone matrix deposition was severely decreased after proteasome inhibitor-
treatment. PI-induced impairment of the chondrogenesis process and failure of linear bone 
growth was probably found mainly due to the induction of resting/stem-like chondrocyte 
apoptosis, and accordingly, GFP reporter accumulation was evident mainly in these cells. 
The stem-like cells in the resting zone have a finite proliferative capacity that is gradually 
depleted (Schrier, Ferns et al. 2006), and any disturbances to this might result in growth 
disturbances (Abad, Meyers et al. 2002). Consistent with this hypothesis, we speculated 
that PI-treated animals would not be able to catch-up. Some tendencies of catch-up 
growth were observed, specifically after MG262-treatment, however, it was not complete. 
Bortezomib-treated mice were followed up to 6 months after cessation of treatment after 
administration of one 2-wk cycle of a clinically relevant dose of bortezomib, and still they 
were found growth retarded as compared to their weight-matched and pair-fed, vehicle-
treated mice. When investigating the underlying molecular/apoptotic pathways after PI-
treatment, we found early accumulation and activation of p53, Bax, and AIF, cleavage of 
caspases, and the executioner protein in the apoptosis cascade, PARP, while the anti-
apoptotic proteins were found to be down-regulated (e.g., Bcl-2 and Bcl-XL). Moreover, 
mitochondrial dysfunction was also observed, which has previously been implicated as 
being a key mechanism involved in apoptosis (Susin, Zamzami et al. 1997). These 
outcomes therefore emphasize the need of finding preventive strategies to protect 
chondrocytes and maintain normal bone growth during PI-treatment in young individuals 
without interfering with the desired anti-cancer effect of PIs. In an attempt to test this, we 
used the synthetic peptide analog to endogenous humanin, [Gly
14
]-Humanin (HNG), 
which has been shown to be a wide-spectrum survival molecule in different cell-types and 
diseases (Xu, Chua et al. 2006; Hoang, Park et al. 2010) with the ability to bind Bax, 
preventing its activation, and thereby protect the cells from apoptosis (Guo, Zhai et al. 
2003). To address our question, human tumor xenograft mouse models, in vitro cultures 
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of human growth plate cartilage, rat metatarsal bones, and both chondrogenic and cancer 
cell lines were applied. Here, we made the novel finding that HNG can rescue from PI-
induced bone growth impairment. Importantly, HNG did not interfere with the desired 
anti-cancer effect of bortezomib. The cytoprotective effect of HNG was associated with a 
protection of resting/stem-like chondrocytes from bortezomib-induced apoptosis, an 
effect mediated through interference with the pro-apoptotic protein, Bax. We also 
confirmed that HNG has the ability to protect cultured human growth plate cartilage from 
the cytotoxic effects of bortezomib.  
 
In conclusion, we strongly recommend linear bone growth and bone mineralization to be 
closely monitored in the current pediatric clinical trials of PIs, and for the future, HNG 
supplementary treatment may be a potential therapy for preventing any undesired 
effects associated with PI treatment in children.    
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8 FUTURE PERSPECTIVES 
Overall, it appears that inhibition of proteasome function in chondrocytes specifically 
induces apoptosis, linking the UPS of protein degradation with the regulation of 
apoptotic cell death in chondrocytes and, in turn, with negative consequences on linear 
bone growth. Our observations indicate a more local effect of PIs in the growth plate, 
although we cannot exclude that other systemic factors other than IGF-I may play a role, 
so this should be further investigated. Consequently, observations from this study suggest 
that bone growth could be suppressed in young individuals treated with PIs. However, it 
should be emphasized that so far, any side effects on linear bone growth in treated 
children are unknown, and one should be cautious when extrapolating pre-clinical data to 
the clinical arena. In accordance, our finding needs to be confirmed in ongoing pediatric 
clinical trials.  
 
We showed that resting/stem-like chondrocytes are the main target of PIs, and that no 
complete catch-up growth occurred after PI-treatment, which emphasizes the 
importance of the resting zone chondrocytes, and that loss of them may lead to loss of 
growth potential, which is also supported by previous studies (Abad, Meyers et al. 2002; 
Schrier, Ferns et al. 2006). However, the fact that we found the “quiescent”/slowly- 
proliferative cells to be most sensitive to PI-treatment is in contrast to other studies that 
have reported that rapidly proliferating cells are most susceptible to PIs (Kisselev and 
Goldberg 2001; Voorhees, Dees et al. 2003). The different sensitivity in terms of 
chondrocytes in the growth plate might be due to a cell-type-specific effect with, for 
example, variable dependence on intact proteasomal function, sensitivity to changes in 
normal protein composition, more efficient PI-uptake, or slower inactivation of PIs. This 
finding , therefore, warrants further investigation.  
 
Due to the skeletal morbidities associated with PI-treatment found during this study, it is 
important to develop strategies that will minimize the risk of complications while still 
maintaining high cure rates. Here we show that HNG-supplementary treatment has the 
ability to reverse the negative effects induced by PIs on bone growth by protecting the 
growth plate, mainly by preventing resting/stem-like chondrocyte apoptosis. Importantly, 
the rescuing effect of chondrocytes by HNG did not interfere with the desired anti-cancer 
effect of bortezomib. Hence, humanin and its analogs are novel, potential cell-survival 
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peptides under substantial investigation in different conditions: there is still a lot to 
explore and learn about them, in other words, knowledge of their stability/half-life, cell-
interaction and binding-sites, full dose- and time response, complete interaction of the 
apoptotic pathways and other factors still needs to be gathered. Furthermore, the long-
term effects of HNG remain to be elucidated, as well as any long-term interference with 
the anti-cancer effect, and/or potential cancer-cell rescue. The observed dual roles of 
HNG acting both as a chondrocyte-protective factor, as well as suppressor of tumor 
growth, are remarkable and need to be further investigated in other tumor models. 
Moreover, our findings of a bone growth rescuing effect by HNG may also have wider 
implications as disturbed growth has been linked to many different types of anti-cancer 
treatments.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 58 
9 ACKNOWLEDGEMENTS 
- Det minsta man är skyldig sina drömmar är att tro på dom -  
There are many persons involved in my exiting journey from start to the finishing line. 
Even more that has been around and supported me during this time. I give me deep 
greetings and thanks to all of you!   
 
Lars Sävendahl, my main supervisor, THANK YOU for taking me into your group. 
With your caring and compassionate personality and your creative, enthusiastic, and 
energetic scientific drive, it has been a great honor and privilege for me to be your 
student. You are truly the engine behind, as well as the great source of inspiration for your 
entire group. Besides science and work, you also arranged several fun/social activities. 
Interestingly, you always voted for something that contained a competition, and I am still 
living on the bowling results from when I won ☺ Thank yous are also extended to your 
wonderful family, especially to your wife Ann-Hilde Sävendahl, for inviting us to your 
nice home with lovely dinners. There are still 2 things I do not get: 1) how you find 
anything in your towering (for me very unordered) piles of papers, notes, books, etc., etc. 
I quote Albert Einstein “If a cluttered desk is a sign of a cluttered mind, of what, then, is 
an empty desk a sign?” 2) I do not for one second, understand where you find all the time 
for all the different top-job-positions you are in: students, clinic, family, etc., etc.!? 
Impressive. 
  
Dionisios Chrysis, my Greek, always-charming co-supervisor, and the oracle over the 
complex apoptosis pathway. Thank you for teaching me a lot about this system, and for 
all your fruitful input during my studies. It has always been a pleasure when you have 
come to visit Sweden and the lab – I would only wish that you would have been closer. I 
will always remember the lab retreat to Patras, in mind and heart, and the nice dinner and 
evening in your home. Thank you.   
 
Vladimir Bykov, my knowledgeable co-supervisor. Thank you for your support and 
participation, your expertise and help during these years, and your always-so-friendly, and 
happy personality. I am grateful for your tricky and important questions, and discussions 
along the way to the defense. We also made a nice attempt with Prima, even though it was 
not successful in our hands – though in yours really it is, and I hope that you will have all 
the success you deserve.   
 
Ylva Hägblad, my advisor, mentor, and friend. Thank you for just being around, 
guidance, cheerfulness, and for the discussions about life in general…over a lunch or 
coffee.  
 
I have had a great time during these years as a PhD-student. I have always enjoyed going 
to work, and the days have always passed faster than one would like  – a big part of this is 
thanks to all of you guys: for your support, the inspiring workplace atmosphere, and for 
being a fantastic gang. There are really no words that can describe the feelings and 
gratefulness I have, but I just hope that all of you know that you are a part of this book, 
and without you this expedition would have been tougher more boring. Please, forgive me 
if I have misspelled any name or forgotten someone.   
 
The wonderful Sävendahl group 
 
Farasat Zaman, my mentor. Endless loads of thanks for all that you have thought and 
done for me during my PhD work! Your always kind, and generous personality, and your 
attitude that everything is possible. Thank you for all our discussions on work and life, I 
 59 
 
truly value your advice and input. You always came up with the deepest, most interesting, 
and sometimes unable-to-answer-questions. On top of this, you are a really good friend 
and a great father. You really left an empty void, that can never be filled when you moved 
to Toronto – but still I am glad you did so for your future career, and I wish you all the 
luck and all the best along the way to the top. 
 
Katja Sundström, my soul mate! I do not know where to start… I am just sooo Happy 
and Thankful that I met YOU! We not only became colleagues, but true life-long friends. 
We started our own club - Growth plate club (GPC), containing deep scientific 
discussions, great drawings/figures, and normally “non-asked questions,” which has been 
a great help for both of us (I guess/hope ☺). You have an enormous heart, and together 
we have shared ups and downs, laughter and tears, a lot of coffee/tea, travel adventures, 
nice dinners, and amazing gifts. I am sure we will continue our journey in life - Together!  
 
Elham Karimian, my Persian fashionista. In addition to all of our scientific discussions, 
your extreme speed and accuracy in dissecting metatarsals, you also bring a lot of 
beauty and joy to the group. We have not only shared rooms during our trips and 
scientific meetings, but also shared a lot of shopping experiences and trends. I do hope 
that you find a way of combining both the clinic and science.        
 
Andrei Chagin. You always have very valuable scientific and technical suggestions. 
Your passion for science, your drive to dig deeper, to understand why biology is the way 
it is – as complex as it is– I truly admire. I am sure that you will find the answer to some 
key question that will lead the way in solving growth problems in the future. It was very 
sad and empty when you moved out from our unit, even though we’ll find you just across 
the street.    
 
Paola Fernandez Vojvodich, my Peruvian friend and our little chatterbox. I do not know 
anyone that has as much energy as you do. You are the sunshine in our group, with your 
always-warm and happy personality, and a fantastic mother to your two daughters. You 
have been my sounding board for the thesis writing, and if I could wish for one thing at 
this moment, that would be to have just one percent of the calmness and belief you had 
during your defense.  
 
Therese Cedervall, Thank you so much for your friendship, your great humor and 
sharing experiences not only scientifically, but also in everyday life. It is excellent to have 
you back again, and all the needed/wanted experiments you perform, you do so structured 
and with the best precision. Now we know that Canine is not “kanin.” ☺  
 
Emelie Benyi, our globetrotter and champagne lady that loves to dance. Thanks for being 
a great friend and fun for trips and moments together.   
 
The latest stars in our team, Bettina Cederquist, my newfound “mumintroll” friend, not 
only in the lab, but also along the track in Hagaparken. Sorry, that I thought you were as 
old as me, or I as young as you =/. Maryam Irvani, thank you for the scientific questions 
and discussions. The best of Luck to both of you. 
 
Terhi Heino, even though you no longer belong to our group, you are still a part of it for 
me. Thank you for the support with all the small and large things; you are a fantastic “go-
and-do-it” type of person, and I am still impressed by what you achieved here. Some 
people want it to happen, some wish it would happen, others make it happen. Thank you 
for taking me out in the tracks along Hagaparken, and for being such a nice person and 
friend. 
 
 
All friends/colleagues in the Pediatric Endocrine Unit 
 
 60 
Olle Söder, our extraordinary BOSS. Thank you for all these years and for your cool and 
nice personality, and fantastic speeches. I am glad you became what you are, and created 
such an excellent scientific environment, and not a guitar-hero-rock star (even though you 
would have been in the top there as well). Thank you for all the great adventures during 
the yearly lab-retreats, the Christmas lunches, and for inviting us to your (and Irene’s) 
amazing home with the (too) strong glögg, the always growing ’skumtomte-bowl’, the 
lovely paintings, gadgets….you name it!  
Martin Ritzén, the true father of our lab. You inspire us all, and are one of my idols. 
Your kind personality, valuable input, cleverness, experience, and the maintenance of the 
clinical perspective are fascinating. I am amazed by how sporty you are.  
Cecilia Camacho-Hübner, it was a true pleasure to have you in the lab with all your 
knowledge, enthusiasm, and chit-chats of all important (and unimportant) things, for 
believing in me and saying so. Thank you a lot for your friendship, and the lovely dinner 
in your home. I really hope we will come and visit you in “the Big Apple.”  
Yvonne Löfgren Blomquist, our head commander of the lab, I wonder what the lab 
would be like without you. Probably a real mess! Endless thanks for all the small and 
large things you have helped me with and taught me, all the laughs, storage “back-ups”, 
and for being a great advice-giver about shoes (especially wedding shoes ;))   
Christine Carlsson-Skwirut, not only the “mother” of the lab together with a few others, 
but also my personal ‘calculator’ that you always can count on.    
Susanne Hallberg, our kind, helpful, and always so well dressed lab secretary. I can 
assure you that you really make people feel welcome in our unit. I am also impressed by 
your feeling for clothes and jewelry, and the fact that you are so sporty.  
Mi Hou, my Chinese, now Swedish-fluently talking friend. I am so impressed with you, 
your strong will, and your achievements, both in science and with the language. I would 
like to have some of your courage and to not be afraid of failing. Thank you for your 
friendship and your fantastic humor and great laughs, and the nice presents I have 
received during the years. 
Britt Masironi, for your kindness, always being so nice and helpful, loaning me things 
whenever needed, and giving me tips & tricks for IHC. 
Lena Sahlin, thank you for sharing your knowledge in reproductive endocrinology and 
joining our journal club meetings. Your valuable input, good discussions both scientific 
and non-scientific, always with clever questions and suggestions.    
Ola Nilsson, my landscape and in-topic scientific friend. I have learned a lot from you, 
from the essential comments/inputs, but mainly from all your excellent reviews. I imply 
your Norrbottniska-calmness in every situation. 
Aida Wahlgren, my mentor (although not officially). Thank you for your support, trust 
and friendship, with remarkable care and compassion for everyone. With always precious 
advice and hints, and your way of explaining things can even make a layperson 
understand.   
Luise Landreh, you are such a well-structured person, with a lot of knowledge and great 
ideas. You have such an easy-going nature, and your quick way of learning is admirable. 
Mona-Lisa Strand, always with a smile and interesting chats of family-life, your rabbits 
and maybe some science in-between as well ;) Ahmed Rheda, my right sided-neighbor, 
and the only guy bringing flowers and paintings to the PhD-room. Thank you for the song 
and guitar play you gave me on my 30
th
 birthday, and for always being happy and your 
great sense of humor. Lars Hagenäs, for your interesting discussions and deep thinking 
about science and life. Rós Kjartansdóttir and Momina Mirza, my temporary roomies, 
thanks for your kind hearts and support. Konstantin Svechnikov, thank you for always 
bringing nice flowers to the lab on “women’s day,” and for being a master of 
 61 
 
steroidogenesis. Irina Svechnikova, always nice and helpful. Jan-Berndt Stukenborg, 
yet another German, with impressive plans, which I hope and think you will fulfill. Thank 
you for all your help and support, especially with microscope matters. I must admit that 
Germans are nice, easy going, and fantastically fun with a great sense of humor. Anenisia 
Andrade, my Brazilian friend, always with a smile on your face, and sunglasses on your 
head. Ulrika Berg, my sporty friend, with a great heart that was sitting next to me for a 
few years. Your strength and determination in life is spectacular. Shahzad Akram, such a 
nice and generous person, with a great mood and always smiling face. 
I would like to express my sincere gratitude for your support and the friendly 
environment: Peter Bang, Vichit Supornsilchai, Blesson C Selvanesam, Taranum 
Sultana, Kerstin Sollerbrant, Eugenia Colon Cervantes, Iuliia Savchuk, Maryana 
Hulchiy, Stephan Späth, Michael Chau, Kirsi Jahnukainen, Karin Reuter, Mikael 
Reimeringer, and Yong-Qing Hua. 
 
 
The collaborators of my papers 
 
Staffan Eksborg, I was blessed when you asked me (at Mona-Lisa’s defense party) to 
enter under your umbrella, and be my statistic-mentor. You are an amazing, positive, and 
fun person, with a smashing message “Everything is possible”! Your door has always 
been open whenever I needed, both for statistic-, scientific- and general life discussions. 
You possess great knowledge within most fields, and it is always so inspiring to visit your 
office (thinks from both me and my son), which almost feels like going to the Zoo, or 
maybe even an Island.☺  
Malin Wickström, fantastically well-ordered and structured, a really fun, easy-going and 
extremely helpful friend. Thank you for all your input, quick and in due time answers to 
mails/sms.  
Per Kogner, always in a happy mood with great input and ideas. Thank you for widening 
my knowledge, by introducing me into the field of cancer and your lovely group. 
Lova Perup Segerström, for the assistance and support, and sharing your expertise in the 
animal facility and during my last study, your liveliness, and energy.    
Lotta Elfman, always so helpful and always finding nothing to be a problem whether big 
or small. Thank you for all the cell culture and animal stuff that you have helped with.  
John-Inge Johnsen, for all your support, high scientific input, and your aim to reach for 
the stars. I must honestly say that from time to time I have had some difficulties to 
understand your Norwegian dialect… 
Henrik Wehtje and staff in the orthopedic clinic, for invaluable help collecting growth 
plate biopsies.  
I would like to convey my appreciation for all your help, support, and advice: Cecilia 
Dyrberg, Anna Kock, Victoria Menendez-Benito, Bengt Fadeel, Nico P. Dantuma, 
Masaharu Takigawa. 
 
 
People making the journey a lot easier 
 
Astrid Häggblad, the “mother” of all PhD-students. Thank you for always being helpful 
anytime needed during my studies.  
Ulf Hörnberg, for your always-too-kind and helpful personality. What would we have 
done without you? You have always provided excellent tissue sections in due time, and 
been very supportive in sharing methods and/or reagents for stainings.  
Wiveka Ekström Vanrillaer, my contact person and master of X-rays, who also became 
my friend. Thank you for your support and interest in my research, and for also getting 
 62 
your attention on to bandy, I am so happy I met you. Do you still keep my little friends on 
the door to your trash can?     
Ann-Christine Eklöf, Josephine Forsberg, Magnus Windahl, Anna-Lena, Kicki, Leo, 
Kickan, P-O, Linda and the entire Animal Facility (AKM), thank you for your 
friendly approach, all your expertise, help, and support whenever needed in animal 
welfare and experiments.  
 
 
My adorable Family and close Friends 
 
My always and ever beloved family: first of all, my best friend (“Love is friendship set on 
fire”) and darling (also soon husband), Olov. Your love, calmness, support, and belief in 
me, has been an immense help along the way, and will for sure be so for the rest of our 
lives – you complete me! “Där du andas, där du älskar, där vill jag leva min stund på 
jorden.”  
Elton – vår älskade lilla Gounge! It is fantastic how one can fall so deeply in love with 
someone from the first sight and ever after. When you came into our lives everything 
changed for the best. “You make all the colors brighter, all beauty more delightful, all joy 
deeper – I love you more than life, our Precious, our Miracle.”  
Mamma Inger and Pappa Tommy - THANK YOU, for your endless and unconditional 
love, support and belief in me. You have taught me the most fundamental things in life 
“Before you act - listen; before you react - think; before you spend – earn; before you 
criticize - wait; before you pray - forgive; before you quit – try.” My wish is to always see 
you healthy and happy. However, I do still wonder if you actually know what I have been 
doing during my PhD!? Anyway, now you have the book☺  
Andreas, my dear little brother, whenever you call or I see you I become happy. It’s 
fascinating how sibling love can grow and become stronger than diamonds. Although we 
have chosen different paths in our professional lives, we are both very passionate about 
what we do. I’m impressed by how you make/want the best for everyone around you, fix 
‘parties’, and your recollection of birthdays, etc. I do hope we will live closer someday, 
maybe time to move up north soon ;)    
My (soon to be) mother- and father-in-law, Ingrid and Lennart. Thank you for taking me 
into your family, for all your love, enthusiasm, and support, and thanks for the relaxation, 
with fabulous trips, adventures, and nice dinners. 
All my love and gratitude to you Cilla, Jenny, and Klas for your support, kindness, and 
nice times together.  
I also send my deepest thankfulness to all other family members.  
 
Barndoms-/fotbolls kompisar, spelare med respektive i Hammarby Bandy. No one 
named, no one forgotten - you know who you are! “We do not remember days, we 
remember moments.” 
 
Finally, a sincere thank you to Karolinska Institutet for this opportunity. 
 
This work was supported by the Swedish Research Council, the Swedish Childhood 
Cancer Foundation, Stiftelsen Frimurare Barnhuset Stockholm, Sällskapet Barnavård, 
HKH Kronprinsessan Lovisas Förening för Barnasjukvård/Stiftelsen Axel Tielmans 
Minnesfond, and Karolinska Institutet. 
 
I declare no conflict of interest in my research within this thesis. 
 
THANK YOU! 
 63 
 
10 BIBLIOGRAPHY 
 
Abad, V., J. L. Meyers, et al. (2002). "The role of the resting zone in growth plate 
chondrogenesis." Endocrinology 143(5): 1851-1857. 
Acheson, R. M. and M. N. Macintyre (1958). "The effects of acute infection and acute 
starvation on skeletal development; a study of young rats." Br J Exp Pathol 39(1): 
37-45. 
Adams, J. (2002). "Development of the proteasome inhibitor PS-341." Oncologist 7(1): 9-
16. 
Adams, J. (2004). "The proteasome: a suitable antineoplastic target." Nat Rev Cancer 
4(5): 349-360. 
Adams, J. and M. Kauffman (2004). "Development of the proteasome inhibitor Velcade 
(Bortezomib)." Cancer Invest 22(2): 304-311. 
Adams, J., V. J. Palombella, et al. (1999). "Proteasome inhibitors: a novel class of potent 
and effective antitumor agents." Cancer Res 59(11): 2615-2622. 
Amizuka, N., J. E. Henderson, et al. (1996). "Programmed cell death of chondrocytes and 
aberrant chondrogenesis in mice homozygous for parathyroid hormone-related 
peptide gene deletion." Endocrinology 137(11): 5055-5067. 
Amling, M., L. Neff, et al. (1997). "Bcl-2 lies downstream of parathyroid hormone-
related peptide in a signaling pathway that regulates chondrocyte maturation 
during skeletal development." J Cell Biol 136(1): 205-213. 
Anderson, H. C. (2003). "Matrix vesicles and calcification." Curr Rheumatol Rep 5(3): 
222-226. 
Ansari, B., P. J. Coates, et al. (1993). "In situ end-labelling detects DNA strand breaks in 
apoptosis and other physiological and pathological states." J Pathol 170(1): 1-8. 
Arlt, A., I. Bauer, et al. (2009). "Increased proteasome subunit protein expression and 
proteasome activity in colon cancer relate to an enhanced activation of nuclear 
factor E2-related factor 2 (Nrf2)." Oncogene 28(45): 3983-3996. 
Athanassiadou, F., A. Tragiannidis, et al. (2005). "Evaluation of bone metabolism in 
children with acute lymphoblastic leukemia after induction chemotherapy 
treatment." Pediatr Hematol Oncol 22(4): 285-289. 
Bachar, A. R., L. Scheffer, et al. (2010). "Humanin is expressed in human vascular walls 
and has a cytoprotective effect against oxidized LDL-induced oxidative stress." 
Cardiovasc Res 88(2): 360-366. 
Baron, J., K. O. Klein, et al. (1994). "Catch-up growth after glucocorticoid excess: a 
mechanism intrinsic to the growth plate." Endocrinology 135(4): 1367-1371. 
Baron, J., K. O. Klein, et al. (1994). "Induction of growth plate cartilage ossification by 
basic fibroblast growth factor." Endocrinology 135(6): 2790-2793. 
Basler, M., C. Lauer, et al. (2009). "The proteasome inhibitor bortezomib enhances the 
susceptibility to viral infection." J Immunol 183(10): 6145-6150. 
Beguiristain, J. L., J. De Salis, et al. (1980). "Experimental scoliosis by epiphysiodesis in 
pigs." Int Orthop 3(4): 317-321. 
Bello, C. E. and S. D. Garrett (1999). "Therapeutic issues in oral glucocorticoid use." 
Lippincotts Prim Care Pract 3(3): 333-341; quiz 342-334. 
Bi, W., J. M. Deng, et al. (1999). "Sox9 is required for cartilage formation." Nat Genet 
22(1): 85-89. 
 64 
Blaney, S. M., M. Bernstein, et al. (2004). "Phase I study of the proteasome inhibitor 
bortezomib in pediatric patients with refractory solid tumors: a Children's 
Oncology Group study (ADVL0015)." J Clin Oncol 22(23): 4804-4809. 
Brignole, C., D. Marimpietri, et al. (2006). "Effect of bortezomib on human 
neuroblastoma cell growth, apoptosis, and angiogenesis." J Natl Cancer Inst 
98(16): 1142-1157. 
Bueno, A. L. and M. A. Czepielewski (2008). "The importance for growth of dietary 
intake of calcium and vitamin D." J Pediatr (Rio J) 84(5): 386-394. 
Burdan, F., J. Szumilo, et al. (2009). "Morphology and physiology of the epiphyseal 
growth plate." Folia Histochem Cytobiol 47(1): 5-16. 
Burkus, J. K. and J. A. Ogden (1984). "Development of the distal femoral epiphysis: a 
microscopic morphological investigation of the zone of Ranvier." J Pediatr Orthop 
4(6): 661-668. 
Cardozo, C. (1993). "Catalytic components of the bovine pituitary multicatalytic 
proteinase complex (proteasome)." Enzyme Protein 47(4-6): 296-305. 
Cavaletti, G., A. Gilardini, et al. (2007). "Bortezomib-induced peripheral neurotoxicity: a 
neurophysiological and pathological study in the rat." Exp Neurol 204(1): 317-
325. 
Chagin, A. S. and L. Savendahl (2007). "GPR30 estrogen receptor expression in the 
growth plate declines as puberty progresses." J Clin Endocrinol Metab 92(12): 
4873-4877. 
Chen, D., M. Frezza, et al. (2011). "Bortezomib as the first proteasome inhibitor 
anticancer drug: current status and future perspectives." Curr Cancer Drug Targets 
11(3): 239-253. 
Chrysis, D., O. Nilsson, et al. (2002). "Apoptosis is developmentally regulated in rat 
growth plate." Endocrine 18(3): 271-278. 
Chrysis, D., E. M. Ritzen, et al. (2003). "Growth retardation induced by dexamethasone is 
associated with increased apoptosis of the growth plate chondrocytes." J 
Endocrinol 176(3): 331-337. 
Ciechanover, A. (1998). "The ubiquitin-proteasome pathway: on protein death and cell 
life." EMBO J 17(24): 7151-7160. 
Cvek, B. (2012). "Proteasome inhibitors." Prog Mol Biol Transl Sci 109: 161-226. 
Danial, N. N. and S. J. Korsmeyer (2004). "Cell death: critical control points." Cell 
116(2): 205-219. 
Day, T. F., X. Guo, et al. (2005). "Wnt/beta-catenin signaling in mesenchymal progenitors 
controls osteoblast and chondrocyte differentiation during vertebrate 
skeletogenesis." Dev Cell 8(5): 739-750. 
De Duve, C. and R. Wattiaux (1966). "Functions of lysosomes." Annu Rev Physiol 28: 
435-492. 
Ehrenberg, B., V. Montana, et al. (1988). "Membrane potential can be determined in 
individual cells from the nernstian distribution of cationic dyes." Biophys J 53(5): 
785-794. 
Elias, L. L., A. Huebner, et al. (2000). "Tall stature in familial glucocorticoid deficiency." 
Clin Endocrinol (Oxf) 53(4): 423-430. 
Elmore, S. (2007). "Apoptosis: a review of programmed cell death." Toxicol Pathol 35(4): 
495-516. 
Erenpreisa, J. and H. I. Roach (1998). "Aberrant death in dark chondrocytes of the avian 
growth plate." Cell Death Differ 5(1): 60-66. 
Eriksson, E., F. Zaman, et al. (2012). "Bortezomib is cytotoxic to the human growth plate 
and permanently impairs bone growth in young mice." PLoS One 7(11): e50523. 
 65 
 
Farnum, C. E. and N. J. Wilsman (1993). "Determination of proliferative characteristics 
of growth plate chondrocytes by labeling with bromodeoxyuridine." Calcif Tissue 
Int 52(2): 110-119. 
Fenteany, G., R. F. Standaert, et al. (1995). "Inhibition of proteasome activities and 
subunit-specific amino-terminal threonine modification by lactacystin." Science 
268(5211): 726-731. 
Foster, J. W., M. A. Dominguez-Steglich, et al. (1994). "Campomelic dysplasia and 
autosomal sex reversal caused by mutations in an SRY-related gene." Nature 
372(6506): 525-530. 
Gafni, R. I. and J. Baron (2000). "Catch-up growth: possible mechanisms." Pediatr 
Nephrol 14(7): 616-619. 
Gafni, R. I., M. Weise, et al. (2001). "Catch-up growth is associated with delayed 
senescence of the growth plate in rabbits." Pediatr Res 50(5): 618-623. 
Garrett, I. R., D. Chen, et al. (2003). "Selective inhibitors of the osteoblast proteasome 
stimulate bone formation in vivo and in vitro." J Clin Invest 111(11): 1771-1782. 
Gavrieli, Y., Y. Sherman, et al. (1992). "Identification of programmed cell death in situ 
via specific labeling of nuclear DNA fragmentation." J Cell Biol 119(3): 493-501. 
Gerber, H. P., T. H. Vu, et al. (1999). "VEGF couples hypertrophic cartilage remodeling, 
ossification and angiogenesis during endochondral bone formation." Nat Med 
5(6): 623-628. 
Gluckman, P. D. (1997). "Endocrine and nutritional regulation of prenatal growth." Acta 
Paediatr Suppl 423: 153-157; discussion 158. 
Gothe, S., Z. Wang, et al. (1999). "Mice devoid of all known thyroid hormone receptors 
are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone 
maturation." Genes Dev 13(10): 1329-1341. 
Grigoriadis, A. E., J. N. Heersche, et al. (1988). "Differentiation of muscle, fat, cartilage, 
and bone from progenitor cells present in a bone-derived clonal cell population: 
effect of dexamethasone." J Cell Biol 106(6): 2139-2151. 
Grigoriadis, A. E., J. N. Heersche, et al. (1996). "Analysis of chondroprogenitor 
frequency and cartilage differentiation in a novel family of clonal chondrogenic 
rat cell lines." Differentiation 60(5): 299-307. 
Grossin, L., S. Etienne, et al. (2004). "Induction of heat shock protein 70 (Hsp70) by 
proteasome inhibitor MG 132 protects articular chondrocytes from cellular death 
in vitro and in vivo." Biorheology 41(3-4): 521-534. 
Grumbach, M. M. (2000). "Estrogen, bone, growth and sex: a sea change in conventional 
wisdom." J Pediatr Endocrinol Metab 13 Suppl 6: 1439-1455. 
Grumbach, M. M. (2004). "Mutations in the synthesis and action of estrogen: the critical 
role in the male of estrogen on pubertal growth, skeletal maturation, and bone 
mass." Ann N Y Acad Sci 1038: 7-13. 
Guo, B., D. Zhai, et al. (2003). "Humanin peptide suppresses apoptosis by interfering with 
Bax activation." Nature 423(6938): 456-461. 
Habu, S., H. Fukui, et al. (1981). "In vivo effects of anti-asialo GM1. I. Reduction of NK 
activity and enhancement of transplanted tumor growth in nude mice." J Immunol 
127(1): 34-38. 
Haeusler, G., I. Walter, et al. (2005). "Localization of matrix metalloproteinases, (MMPs) 
their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth 
plates of children and adolescents indicates a role for MMPs in human postnatal 
growth and skeletal maturation." Calcif Tissue Int 76(5): 326-335. 
Hale, L. V., R. J. Galvin, et al. (2007). "PINP: a serum biomarker of bone formation in the 
rat." Bone 40(4): 1103-1109. 
 66 
Hamner, J. B., P. V. Dickson, et al. (2007). "Bortezomib inhibits angiogenesis and 
reduces tumor burden in a murine model of neuroblastoma." Surgery 142(2): 185-
191. 
Harada, M., Y. Habata, et al. (2004). "N-formylated humanin activates both formyl 
peptide receptor-like 1 and 2." Biochemical and Biophysical Research 
Communications 324(1): 255-261. 
Hashimoto, Y., M. Kurita, et al. (2009). "Identification of soluble WSX-1 not as a 
dominant-negative but as an alternative functional subunit of a receptor for an 
anti-Alzheimer's disease rescue factor Humanin." Biochem Biophys Res Commun 
389(1): 95-99. 
Hashimoto, Y., T. Niikura, et al. (2001). "Detailed characterization of neuroprotection by 
a rescue factor humanin against various Alzheimer's disease-relevant insults." J 
Neurosci 21(23): 9235-9245. 
Hashimoto, Y., T. Niikura, et al. (2001). "A rescue factor abolishing neuronal cell death 
by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proc Natl 
Acad Sci U S A 98(11): 6336-6341. 
Hashimoto, Y., H. Suzuki, et al. (2005). "Involvement of tyrosine kinases and STAT3 in 
Humanin-mediated neuroprotection." Life Sci 77(24): 3092-3104. 
Herrmann, J., A. M. Saguner, et al. (2007). "Chronic proteasome inhibition contributes to 
coronary atherosclerosis." Circ Res 101(9): 865-874. 
Hershko, A., A. Ciechanover, et al. (1980). "Proposed role of ATP in protein breakdown: 
conjugation of protein with multiple chains of the polypeptide of ATP-dependent 
proteolysis." Proc Natl Acad Sci U S A 77(4): 1783-1786. 
Hershko, A., A. Ciechanover, et al. (1981). "Identification of the active amino acid 
residue of the polypeptide of ATP-dependent protein breakdown." J Biol Chem 
256(4): 1525-1528. 
Hideshima, T., P. Richardson, et al. (2001). "The proteasome inhibitor PS-341 inhibits 
growth, induces apoptosis, and overcomes drug resistance in human multiple 
myeloma cells." Cancer Res 61(7): 3071-3076. 
Hoang, P. T., P. Park, et al. (2010). "The neurosurvival factor Humanin inhibits beta-cell 
apoptosis via signal transducer and activator of transcription 3 activation and 
delays and ameliorates diabetes in nonobese diabetic mice." Metabolism 59(3): 
343-349. 
Holick, M. F. (2007). "Optimal vitamin D status for the prevention and treatment of 
osteoporosis." Drugs Aging 24(12): 1017-1029. 
Horton, T. M., D. Pati, et al. (2007). "A phase 1 study of the proteasome inhibitor 
bortezomib in pediatric patients with refractory leukemia: a Children's Oncology 
Group study." Clin Cancer Res 13(5): 1516-1522. 
Horton, W. A. (2003). "Skeletal development: insights from targeting the mouse 
genome." Lancet 362(9383): 560-569. 
Hoshino, T., T. Nagashima, et al. (1989). "Variability in the proliferative potential of 
human gliomas." J Neurooncol 7(2): 137-143. 
Houghton, P. J., C. L. Morton, et al. (2008). "Initial testing (stage 1) of the proteasome 
inhibitor bortezomib by the pediatric preclinical testing program." Pediatr Blood 
Cancer 50(1): 37-45. 
Hunziker, E. B. (1994). "Mechanism of longitudinal bone growth and its regulation by 
growth plate chondrocytes." Microsc Res Tech 28(6): 505-519. 
Hunziker, E. B. and R. K. Schenk (1989). "Physiological mechanisms adopted by 
chondrocytes in regulating longitudinal bone growth in rats." J Physiol 414: 55-
71. 
 67 
 
Hunziker, E. B., R. K. Schenk, et al. (1987). "Quantitation of chondrocyte performance in 
growth-plate cartilage during longitudinal bone growth." J Bone Joint Surg Am 
69(2): 162-173. 
Ikonen, M., B. Liu, et al. (2003). "Interaction between the Alzheimer's survival peptide 
humanin and insulin-like growth factor-binding protein 3 regulates cell survival 
and apoptosis." Proc Natl Acad Sci U S A 100(22): 13042-13047. 
Inada, M., T. Yasui, et al. (1999). "Maturational disturbance of chondrocytes in Cbfa1-
deficient mice." Dev Dyn 214(4): 279-290. 
Irmler, M., M. Thome, et al. (1997). "Inhibition of death receptor signals by cellular 
FLIP." Nature 388(6638): 190-195. 
Isaksson, O. G., J. O. Jansson, et al. (1982). "Growth hormone stimulates longitudinal 
bone growth directly." Science 216(4551): 1237-1239. 
Iyama, K., Y. Ninomiya, et al. (1991). "Spatiotemporal pattern of type X collagen gene 
expression and collagen deposition in embryonic chick vertebrae undergoing 
endochondral ossification." Anat Rec 229(4): 462-472. 
Kaiser, M. F., U. Heider, et al. (2013). "The Proteasome Inhibitor Bortezomib Stimulates 
Osteoblastic Differentiation of Human Osteoblast Precursors via Upregulation of 
Vitamin D Receptor Signalling." Eur J Haematol. 
Kane, R. C., P. F. Bross, et al. (2003). "Velcade: U.S. FDA approval for the treatment of 
multiple myeloma progressing on prior therapy." Oncologist 8(6): 508-513. 
Kane, R. C., R. Dagher, et al. (2007). "Bortezomib for the treatment of mantle cell 
lymphoma." Clin Cancer Res 13(18 Pt 1): 5291-5294. 
Kanoh, M., G. Takemura, et al. (1999). "Significance of myocytes with positive DNA in 
situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not 
apoptosis but DNA repair." Circulation 99(21): 2757-2764. 
Karlberg, J. (1987). "On the modelling of human growth." Stat Med 6(2): 185-192. 
Kaufman, MH. (1992). "The atlas of mouse development." Academic Press, London. 
Kember, N. F. and H. A. Sissons (1976). "Quantitative histology of the human growth 
plate." J Bone Joint Surg Br 58-B(4): 426-435. 
Kerr, J. F., A. H. Wyllie, et al. (1972). "Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics." Br J Cancer 26(4): 239-257. 
Khan, K., H. A. McKay, et al. (2000). "Does childhood and adolescence provide a unique 
opportunity for exercise to strengthen the skeleton?" J Sci Med Sport 3(2): 150-
164. 
Kirk, J. A., P. Raghupathy, et al. (1987). "Growth failure and growth-hormone deficiency 
after treatment for acute lymphoblastic leukaemia." Lancet 1(8526): 190-193. 
Kisselev, A. F. and A. L. Goldberg (2001). "Proteasome inhibitors: from research tools to 
drug candidates." Chem Biol 8(8): 739-758. 
Kobayashi, T., D. W. Soegiarto, et al. (2005). "Indian hedgehog stimulates periarticular 
chondrocyte differentiation to regulate growth plate length independently of 
PTHrP." J Clin Invest 115(7): 1734-1742. 
Komarov, P. G., E. A. Komarova, et al. (1999). "A chemical inhibitor of p53 that protects 
mice from the side effects of cancer therapy." Science 285(5434): 1733-1737. 
Komarova, E. A. and A. V. Gudkov (1998). "Could p53 be a target for therapeutic 
suppression?" Semin Cancer Biol 8(5): 389-400. 
Kortuem, K. M. and A. K. Stewart (2013). "Carfilzomib." Blood 121(6): 893-897. 
Kronenberg, H. M. (2003). "Developmental regulation of the growth plate." Nature 
423(6937): 332-336. 
Kuhn, K. and M. Lotz (2001). "Regulation of CD95 (Fas/APO-1)-induced apoptosis in 
human chondrocytes." Arthritis Rheum 44(7): 1644-1653. 
 68 
Kumatori, A., K. Tanaka, et al. (1990). "Abnormally high expression of proteasomes in 
human leukemic cells." Proc Natl Acad Sci U S A 87(18): 7071-7075. 
Le Roith, D., C. Bondy, et al. (2001). "The somatomedin hypothesis: 2001." Endocr Rev 
22(1): 53-74. 
Lefebvre, V. and B. de Crombrugghe (1998). "Toward understanding SOX9 function in 
chondrocyte differentiation." Matrix Biol 16(9): 529-540. 
Legeai-Mallet, L., C. Benoist-Lasselin, et al. (1998). "Fibroblast growth factor receptor 3 
mutations promote apoptosis but do not alter chondrocyte proliferation in 
thanatophoric dysplasia." J Biol Chem 273(21): 13007-13014. 
Li, P., D. Nijhawan, et al. (1997). "Cytochrome c and dATP-dependent formation of 
Apaf-1/caspase-9 complex initiates an apoptotic protease cascade." Cell 91(4): 
479-489. 
Lightcap, E. S., T. A. McCormack, et al. (2000). "Proteasome inhibition measurements: 
clinical application." Clin Chem 46(5): 673-683. 
Lindsten, K., V. Menendez-Benito, et al. (2003). "A transgenic mouse model of the 
ubiquitin/proteasome system." Nat Biotechnol 21(8): 897-902. 
Liu, J. L., A. Grinberg, et al. (1998). "Insulin-like growth factor-I affects perinatal 
lethality and postnatal development in a gene dosage-dependent manner: 
manipulation using the Cre/loxP system in transgenic mice." Mol Endocrinol 
12(9): 1452-1462. 
Lopez-Bermejo, A., C. K. Buckway, et al. (2000). "Genetic defects of the growth 
hormone-insulin-like growth factor axis." Trends Endocrinol Metab 11(2): 39-49. 
Luciano, F., D. Zhai, et al. (2005). "Cytoprotective peptide humanin binds and inhibits 
proapoptotic Bcl-2/Bax family protein BimEL." J Biol Chem 280(16): 15825-
15835. 
Lunstrum, G. P., D. R. Keene, et al. (1999). "Chondrocyte differentiation in a rat 
mesenchymal cell line." J Histochem Cytochem 47(1): 1-6. 
Luo, X., I. Budihardjo, et al. (1998). "Bid, a Bcl2 interacting protein, mediates 
cytochrome c release from mitochondria in response to activation of cell surface 
death receptors." Cell 94(4): 481-490. 
Lupu, F., J. D. Terwilliger, et al. (2001). "Roles of growth hormone and insulin-like 
growth factor 1 in mouse postnatal growth." Dev Biol 229(1): 141-162. 
Ma, W., H. Kantarjian, et al. (2009). "Proteasome enzymatic activities in plasma as risk 
stratification of patients with acute myeloid leukemia and advanced-stage 
myelodysplastic syndrome." Clin Cancer Res 15(11): 3820-3826. 
Mamiya, T. and M. Ukai (2001). "[Gly(14)]-Humanin improved the learning and memory 
impairment induced by scopolamine in vivo." Br J Pharmacol 134(8): 1597-1599. 
Maor, G., M. Rochwerger, et al. (2002). "Leptin acts as a growth factor on the 
chondrocytes of skeletal growth centers." J Bone Miner Res 17(6): 1034-1043. 
Meijer, A. J. and P. Codogno (2004). "Regulation and role of autophagy in mammalian 
cells." Int J Biochem Cell Biol 36(12): 2445-2462. 
Messinger, Y., P. Gaynon, et al. (2010). "Phase I study of bortezomib combined with 
chemotherapy in children with relapsed childhood acute lymphoblastic leukemia 
(ALL): a report from the therapeutic advances in childhood leukemia (TACL) 
consortium." Pediatr Blood Cancer 55(2): 254-259. 
Miao, J., W. Zhang, et al. (2008). "S14G-Humanin ameliorates Abeta25-35-induced 
behavioral deficits by reducing neuroinflammatory responses and apoptosis in 
mice." Neuropeptides 42(5-6): 557-567. 
 69 
 
Michaelis, M., I. Fichtner, et al. (2006). "Anti-cancer effects of bortezomib against 
chemoresistant neuroblastoma cell lines in vitro and in vivo." Int J Oncol 28(2): 
439-446. 
Morton, C. L. and P. J. Houghton (2007). "Establishment of human tumor xenografts in 
immunodeficient mice." Nat Protoc 2(2): 247-250. 
Mosmann, T. (1983). "Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays." J Immunol Methods 65(1-2): 
55-63. 
Mukherjee, S., N. Raje, et al. (2008). "Pharmacologic targeting of a stem/progenitor 
population in vivo is associated with enhanced bone regeneration in mice." J Clin 
Invest 118(2): 491-504. 
Muscal, J. A., P. A. Thompson, et al. (2013). "A phase I trial of vorinostat and bortezomib 
in children with refractory or recurrent solid tumors: A Children's Oncology 
Group phase I consortium study (ADVL0916)." Pediatr Blood Cancer 60(3): 390-
395. 
Muzumdar, R. H., D. M. Huffman, et al. (2009). "Humanin: a novel central regulator of 
peripheral insulin action." PLoS One 4(7): e6334. 
Muzumdar, R. H., D. M. Huffman, et al. (2010). "Acute humanin therapy attenuates 
myocardial ischemia and reperfusion injury in mice." Arterioscler Thromb Vasc 
Biol 30(10): 1940-1948. 
Myung, J., K. B. Kim, et al. (2001). "The ubiquitin-proteasome pathway and proteasome 
inhibitors." Med Res Rev 21(4): 245-273. 
Niikura, T., Y. Hashimoto, et al. (2003). "A tripartite motif protein TRIM11 binds and 
destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-
relevant insults." Eur J Neurosci 17(6): 1150-1158. 
Nilsson, A., J. Isgaard, et al. (1986). "Regulation by growth hormone of number of 
chondrocytes containing IGF-I in rat growth plate." Science 233(4763): 571-574. 
Nilsson, O. and J. Baron (2004). "Fundamental limits on longitudinal bone growth: 
growth plate senescence and epiphyseal fusion." Trends Endocrinol Metab 15(8): 
370-374. 
Nilsson, O., D. Chrysis, et al. (2003). "Localization of estrogen receptors-alpha and -beta 
and androgen receptor in the human growth plate at different pubertal stages." J 
Endocrinol 177(2): 319-326. 
Oeffinger, K. C. and M. M. Hudson (2004). "Long-term complications following 
childhood and adolescent cancer: foundations for providing risk-based health care 
for survivors." CA Cancer J Clin 54(4): 208-236. 
Oeffinger, K. C., A. C. Mertens, et al. (2006). "Chronic health conditions in adult 
survivors of childhood cancer." N Engl J Med 355(15): 1572-1582. 
Oltvai, Z. N., C. L. Milliman, et al. (1993). "Bcl-2 heterodimerizes in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death." Cell 74(4): 
609-619. 
Omura, S., T. Fujimoto, et al. (1991). "Lactacystin, a novel microbial metabolite, induces 
neuritogenesis of neuroblastoma cells." J Antibiot (Tokyo) 44(1): 113-116. 
Ornitz, D. M. and P. J. Marie (2002). "FGF signaling pathways in endochondral and 
intramembranous bone development and human genetic disease." Genes Dev 
16(12): 1446-1465. 
Oyajobi, B. O., I. R. Garrett, et al. (2007). "Stimulation of new bone formation by the 
proteasome inhibitor, bortezomib: implications for myeloma bone disease." Br J 
Haematol 139(3): 434-438. 
 70 
Oz, O. K., R. Millsaps, et al. (2001). "Expression of aromatase in the human growth 
plate." J Mol Endocrinol 27(2): 249-253. 
Ozata, M., I. C. Ozdemir, et al. (1999). "Human leptin deficiency caused by a missense 
mutation: multiple endocrine defects, decreased sympathetic tone, and immune 
system dysfunction indicate new targets for leptin action, greater central than 
peripheral resistance to the effects of leptin, and spontaneous correction of leptin-
mediated defects." J Clin Endocrinol Metab 84(10): 3686-3695. 
Pandit, B. and A. L. Gartel (2011). "Proteasome inhibitors induce p53-independent 
apoptosis in human cancer cells." Am J Pathol 178(1): 355-360. 
Parker, E. A., A. Hegde, et al. (2007). "Spatial and temporal regulation of GH-IGF-related 
gene expression in growth plate cartilage." J Endocrinol 194(1): 31-40. 
Pennisi, A., X. Li, et al. (2009). "The proteasome inhibitor, bortezomib suppresses 
primary myeloma and stimulates bone formation in myelomatous and 
nonmyelomatous bones in vivo." Am J Hematol 84(1): 6-14. 
Perry, R. J., C. Farquharson, et al. (2008). "The role of sex steroids in controlling pubertal 
growth." Clin Endocrinol (Oxf) 68(1): 4-15. 
Peters, J. M., W. W. Franke, et al. (1994). "Distinct 19 S and 20 S subcomplexes of the 26 
S proteasome and their distribution in the nucleus and the cytoplasm." J Biol 
Chem 269(10): 7709-7718. 
Pogue, R. and K. Lyons (2006). "BMP signaling in the cartilage growth plate." Curr Top 
Dev Biol 76: 1-48. 
Prader, A., J. M. Tanner, et al. (1963). "Catch-up growth following illness or starvation. 
An example of developmental canalization in man." J Pediatr 62: 646-659. 
Rajkumar, S. V., P. G. Richardson, et al. (2005). "Proteasome inhibition as a novel 
therapeutic target in human cancer." J Clin Oncol 23(3): 630-639. 
Roach, H. I., T. Aigner, et al. (2004). "Chondroptosis: a variant of apoptotic cell death in 
chondrocytes?" Apoptosis 9(3): 265-277. 
Roach, H. I. and J. Erenpreisa (1996). "The phenotypic switch from chondrocytes to 
bone-forming cells involves asymmetric cell division and apoptosis." Connect 
Tissue Res 35(1-4): 85-91. 
Roach, H. I., G. Mehta, et al. (2003). "Temporal analysis of rat growth plates: cessation of 
growth with age despite presence of a physis." J Histochem Cytochem 51(3): 373-
383. 
Robson, H., E. Anderson, et al. (1998). "Chemotherapeutic agents used in the treatment of 
childhood malignancies have direct effects on growth plate chondrocyte 
proliferation." J Endocrinol 157(2): 225-235. 
Robson, H., T. Siebler, et al. (2000). "Thyroid hormone acts directly on growth plate 
chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion 
and cell proliferation." Endocrinology 141(10): 3887-3897. 
Rosenfeld, R. G., A. L. Rosenbloom, et al. (1994). "Growth hormone (GH) insensitivity 
due to primary GH receptor deficiency." Endocr Rev 15(3): 369-390. 
Rossi, D. and G. Gaidano (2003). "Messengers of cell death: apoptotic signaling in health 
and disease." Haematologica 88(2): 212-218. 
Salmon, W. D., Jr. and W. H. Daughaday (1957). "A hormonally controlled serum factor 
which stimulates sulfate incorporation by cartilage in vitro." J Lab Clin Med 
49(6): 825-836. 
Schipani, E., H. E. Ryan, et al. (2001). "Hypoxia in cartilage: HIF-1alpha is essential for 
chondrocyte growth arrest and survival." Genes Dev 15(21): 2865-2876. 
Schrier, L., S. P. Ferns, et al. (2006). "Depletion of resting zone chondrocytes during 
growth plate senescence." J Endocrinol 189(1): 27-36. 
 71 
 
Schriock, E. A., M. J. Schell, et al. (1991). "Abnormal growth patterns and adult short 
stature in 115 long-term survivors of childhood leukemia." J Clin Oncol 9(3): 400-
405. 
Schwartz, R. and T. Davidson (2004). "Pharmacology, pharmacokinetics, and practical 
applications of bortezomib." Oncology (Williston Park) 18(14 Suppl 11): 14-21. 
Schweichel, J. U. and H. J. Merker (1973). "The morphology of various types of cell 
death in prenatal tissues." Teratology 7(3): 253-266. 
Shapiro, I. M., C. S. Adams, et al. (2005). "Fate of the hypertrophic chondrocyte: 
microenvironmental perspectives on apoptosis and survival in the epiphyseal 
growth plate." Birth Defects Res C Embryo Today 75(4): 330-339. 
Siebler, T., S. M. Shalet, et al. (2002). "Effects of chemotherapy on bone metabolism and 
skeletal growth." Horm Res 58 Suppl 1: 80-85. 
Smith, M. A., N. L. Seibel, et al. (2010). "Outcomes for children and adolescents with 
cancer: challenges for the twenty-first century." J Clin Oncol 28(15): 2625-2634. 
Sotos, J. F. (1996). "Overgrowth. Hormonal Causes." Clin Pediatr (Phila) 35(11): 579-
590. 
Spagnoli, A., V. Hwa, et al. (2001). "Antiproliferative effects of insulin-like growth 
factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. 
relationship to differentiation stage." J Biol Chem 276(8): 5533-5540. 
St-Jacques, B., M. Hammerschmidt, et al. (1999). "Indian hedgehog signaling regulates 
proliferation and differentiation of chondrocytes and is essential for bone 
formation." Genes Dev 13(16): 2072-2086. 
Steppan, C. M., D. T. Crawford, et al. (2000). "Leptin is a potent stimulator of bone 
growth in ob/ob mice." Regul Pept 92(1-3): 73-78. 
Stevens, D. A. and G. R. Williams (1999). "Hormone regulation of chondrocyte 
differentiation and endochondral bone formation." Mol Cell Endocrinol 151(1-2): 
195-204. 
Susin, S. A., N. Zamzami, et al. (1997). "The central executioner of apoptosis: multiple 
connections between protease activation and mitochondria in Fas/APO-1/CD95- 
and ceramide-induced apoptosis." J Exp Med 186(1): 25-37. 
Tajima, H., M. Kawasumi, et al. (2005). "A humanin derivative, S14G-HN, prevents 
amyloid-beta-induced memory impairment in mice." J Neurosci Res 79(5): 714-
723. 
Takigawa, M., K. Tajima, et al. (1989). "Establishment of a clonal human 
chondrosarcoma cell line with cartilage phenotypes." Cancer Res 49(14): 3996-
4002. 
Tanner, J. M. (1963). "Regulation of Growth in Size in Mammals." Nature 199: 845-850. 
Taupin, P. (2007). "BrdU immunohistochemistry for studying adult neurogenesis: 
paradigms, pitfalls, limitations, and validation." Brain Res Rev 53(1): 198-214. 
Thorburn, A. (2004). "Death receptor-induced cell killing." Cell Signal 16(2): 139-144. 
Thun-Hohenstein, L., H. Frisch, et al. (1992). "Growth after radiotherapy and 
chemotherapy in children with leukemia or lymphoma." Horm Res 37(3): 91-95. 
Tivesten, A., S. Moverare-Skrtic, et al. (2004). "Additive protective effects of estrogen 
and androgen treatment on trabecular bone in ovariectomized rats." J Bone Miner 
Res 19(11): 1833-1839. 
Turner, R. T. (1994). "Cancellous bone turnover in growing rats: time-dependent changes 
in association between calcein label and osteoblasts." J Bone Miner Res 9(9): 
1419-1424. 
van der Eerden, B. C., M. Karperien, et al. (2003). "Systemic and local regulation of the 
growth plate." Endocr Rev 24(6): 782-801. 
 72 
van der Eerden, B. C., N. P. van Til, et al. (2002). "Gender differences in expression of 
androgen receptor in tibial growth plate and metaphyseal bone of the rat." Bone 
30(6): 891-896. 
van der Sluis, I. M., M. M. van den Heuvel-Eibrink, et al. (2002). "Altered bone mineral 
density and body composition, and increased fracture risk in childhood acute 
lymphoblastic leukemia." J Pediatr 141(2): 204-210. 
van Gaalen, S. M., M. C. Kruyt, et al. (2010). "Use of fluorochrome labels in in vivo bone 
tissue engineering research." Tissue Eng Part B Rev 16(2): 209-217. 
Wang, J., J. Zhou, et al. (2004). "Evidence supporting dual, IGF-I-independent and IGF-I-
dependent, roles for GH in promoting longitudinal bone growth." J Endocrinol 
180(2): 247-255. 
Wang, X., A. Ottosson, et al. (2009). "Proteasome inhibition induces apoptosis in primary 
human natural killer cells and suppresses NKp46-mediated cytotoxicity." 
Haematologica 94(4): 470-478. 
Watanabe, H., J. Bohensky, et al. (2008). "Hypoxic induction of UCP3 in the growth 
plate: UCP3 suppresses chondrocyte autophagy." J Cell Physiol 216(2): 419-425. 
Wilkins, L. (1965). "The Diagnosis and Treatment of Endocrine Disorders in Childhood 
and Adolescence (3rd Ed.)." Thomas, Springfield, IL. 
Williams, G. R., H. Robson, et al. (1998). "Thyroid hormone actions on cartilage and 
bone: interactions with other hormones at the epiphyseal plate and effects on 
linear growth." J Endocrinol 157(3): 391-403. 
Wilsman, N. J., C. E. Farnum, et al. (1996). "Differential growth by growth plates as a 
function of multiple parameters of chondrocytic kinetics." J Orthop Res 14(6): 
927-936. 
Wit, J. M., N. M. Drayer, et al. (1989). "Total deficiency of growth hormone and 
prolactin, and partial deficiency of thyroid stimulating hormone in two Dutch 
families: a new variant of hereditary pituitary deficiency." Horm Res 32(5-6): 
170-177. 
von Metzler, I., H. Krebbel, et al. (2007). "Bortezomib inhibits human 
osteoclastogenesis." Leukemia 21(9): 2025-2034. 
Woods, K. A., C. Camacho-Hubner, et al. (1996). "Intrauterine growth retardation and 
postnatal growth failure associated with deletion of the insulin-like growth factor I 
gene." N Engl J Med 335(18): 1363-1367. 
Voorhees, P. M., E. C. Dees, et al. (2003). "The proteasome as a target for cancer 
therapy." Clin Cancer Res 9(17): 6316-6325. 
Vortkamp, A., K. Lee, et al. (1996). "Regulation of rate of cartilage differentiation by 
Indian hedgehog and PTH-related protein." Science 273(5275): 613-622. 
Wu, S. and F. De Luca (2006). "Inhibition of the proteasomal function in chondrocytes 
down-regulates growth plate chondrogenesis and longitudinal bone growth." 
Endocrinology 147(8): 3761-3768. 
Xian, C. J., J. C. Cool, et al. (2006). "Damage and recovery of the bone growth 
mechanism in young rats following 5-fluorouracil acute chemotherapy." J Cell 
Biochem 99(6): 1688-1704. 
Xian, C. J., J. C. Cool, et al. (2007). "Effects of etoposide and cyclophosphamide acute 
chemotherapy on growth plate and metaphyseal bone in rats." Cancer Biol Ther 
6(2): 170-177. 
Xu, X., C. C. Chua, et al. (2006). "Humanin is a novel neuroprotective agent against 
stroke." Stroke 37(10): 2613-2619. 
Yang, F., V. Jove, et al. (2012). "Bortezomib induces apoptosis and growth suppression in 
human medulloblastoma cells, associated with inhibition of AKT and NF-kB 
 73 
 
signaling, and synergizes with an ERK inhibitor." Cancer Biol Ther 13(6): 349-
357. 
Zaman, F., B. Fadeel, et al. (2008). "Proteasome inhibition therapies in childhood cancer." 
Leukemia 22(4): 883-884; author reply 884-885. 
Zaman, F., V. Menendez-Benito, et al. (2007). "Proteasome inhibition up-regulates p53 
and apoptosis-inducing factor in chondrocytes causing severe growth retardation 
in mice." Cancer Res 67(20): 10078-10086. 
Zangari, M., D. Esseltine, et al. (2005). "Response to bortezomib is associated to 
osteoblastic activation in patients with multiple myeloma." Br J Haematol 131(1): 
71-73. 
Zangari, M., E. Terpos, et al. (2012). "Impact of bortezomib on bone health in myeloma: a 
review of current evidence." Cancer Treat Rev 38(8): 968-980. 
Zenmyo, M., S. Komiya, et al. (1996). "Morphological and biochemical evidence for 
apoptosis in the terminal hypertrophic chondrocytes of the growth plate." J Pathol 
180(4): 430-433. 
Zhai, D., F. Luciano, et al. (2005). "Humanin binds and nullifies Bid activity by blocking 
its activation of Bax and Bak." J Biol Chem 280(16): 15815-15824. 
Zou, P., Y. Ding, et al. (2003). "Humanin peptides block calcium influx of rat 
hippocampal neurons by altering fibrogenesis of Abeta(1-40)." Peptides 24(5): 
679-685. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
